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Abstract 
 
Metabolic reprogramming in cancer cells has recently been connected to IF1, 
a key regulator of ATP synthase activity, which is found to be overexpressed 
in many human carcinomas. Considering the pivotal role of mitochondria 
inside the cells, mitochondrial alteration is crucial for tumors to grow and IF1 
may help tumor progression by conserving cellular ATP in hypoxic 
conditions. Although the inhibitor has being deeply investigated, its role in 
tumorigenesis and/or cancer progression is still debated. Therefore, we 
prepared stable IF1-silenced clones from the human osteosarcoma 143B cell 
line and assayed the main bioenergetic parameters, to examine both the role 
played by IF1 and the mechanism the inhibitor adopts in tumor cells to 
control mitochondrial mass, structure and function, besides regulate energy 
homeostasis. In our model, overall data indicate that the inhibitor protein can 
enhance the rate of ATP synthesis via OXPHOS, thus representing a successful 
strategy used by cancer cells to produce more energy and proliferate under 
oxygen availability. 
In addition, recent literature has clearly evidenced that epigenetic alterations 
play a crucial role in modifying genes expression and modulating cancer cell 
metabolism, sustaining tumor growth and dissemination. Moreover, these 
molecules have been recently addressed as responsible for chemoresistance 
in several common therapies, prompting further investigations over miRNAs-
driven metabolic alterations. However, compelling data emerging from a 
microRNA expression profiling, revealed an up-regulation of four miRNAs in 
BRAF(V600E) mutation-carrying melanomas, when developing resistance to  
BRAF-I, the major breakthrough in the treatment of these poor-prognosis 
malignancies. Intriguingly, three of these miRNAs target SUFU, a protein 
inhibiting the Shh pathway, which is altered in various forms of cancer. Since 
therapeutic failure still accounts for death in over 90% of patients with 
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metastatic cancers, we also focused on the role exerted by these miRNAs in 
the molecular mechanisms of drug-resistance.  
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Introduction  
 
1- Cancer and metabolism 
Classically, cancer has been considered as a set of diseases driven by 
progressive genetic abnormalities, including mutations in oncogenes and 
tumor-suppressor genes, as well as chromosomal abnormalities: as a result, 
these changes lead cancer cells undergoing uncontrolled cell division and 
evasion from mechanism of cell death, along with a high potential to spread 
and metastasize in other parts of the body.  
Particularly, in the last decades, an increasing attention has been given to the 
metabolic signature of cancer cells, as evidenced by plenty of data reporting 
that a metabolic reprogramming occurs in these cells, resulting in a 
predominantly glycolytic phenotype (1). The importance of these metabolic 
changes was initially highlighted by Sir Otto Warburg, who first postulated 
that changes in metabolism are fundamental in the origin and progression of 
cancer (2). Actually, he first hypothesized that such changes enable cancer 
cells to meet the large biosynthetic demand associated with rapid cell growth 
and division, along with the high energy requirements of tumor cells; 
however, this hypothesis was only marginally considered for long time. 
Indeed, unlike non-transformed cells, which typically rely on oxidative 
phosphorylation to supply the majority of energy demand, cancer cells are 
often characterized by mitochondrial dysfunction and a higher glycolysis 
rate, even in presence of abundant oxygen.  
This metabolic reprogramming in cancer cells may stem from several 
mechanisms, like the above mentioned mutations in somatic genes, that play 
a role in promoting or suppressing malignant progression, or result from 
adaptation to low-oxygen environment within tumor. However, it is 
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important to note that OXPHOS activity, even though reduced, is not 
suppressed in tumor cells and that mitochondria are the main crossroads of 
important metabolic regulation in cancer: up-regulation of OXPHOS has been 
recently demonstrated in breast cancer (3) and an increase in oxygen 
consumption, together with a prominent expression of mitochondrial 
function genes have also been reported (4). Furthermore, mitochondria are 
the main intracellular producers of reactive oxygen species (ROS), that are 
typically increased in cancer and may interact with mtDNA, producing 
mutations in mitochondrial encoded protein that are crucial for 
mitochondrial functioning, including alteration of the bioenergetic and 
biosynthetic state of cancer cells.  
All these features, often referred as “hallmarks of cancer” have recently been 
connected to IF1, an endogenous protein encoded by nuclear DNA, which 
plays a crucial role in regulating ATP synthase activity inside mitochondria. 
Long investigated in the mechanisms of ischemia and reperfusion, indeed, 
this inhibitor is now under investigation for other potential roles, spanning 
from physiological and pathological payrolls, that may contribute to 
modulate energy metabolism, as will be further addressed in the following 
sections, with particular relevance in cancer formation and progression. 
Additionally, despite large evidence support the idea that oncogenic 
activation of signal transduction pathways and transcription factors are 
responsible for metabolic reprogramming, it has more recently become 
apparent that cancer is also driven by epigenetic alterations (5), functionally 
relevant modifications to the genome that do not involve a change in the 
nucleotide sequence, but are critical for gene expression and tumor cell 
reprogramming at cellular, genetic, biochemical and metabolic levels.  
Particularly, great relevance has been recently given to the small RNAs 
molecules, known as microRNAs (or miRNAs), short, non-protein-coding 
RNAs of about 20 nucleotides in length, recognized to alter gene expression 
at a post-transcriptional level, targeting protein-coding genes and playing a 
role in almost all aspects of cancer biology (6). 
Since it was discovered that miRNAs are abnormally expressed in cancer, in 
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2002 (7), accumulative studies showed that miRNAs play important roles in 
tumor growth and a large number of miRNAs have been identified to regulate 
cancer metabolism. Actually, several studies demonstrated that a large 
number of microRNAs are under the control of various metabolic stimuli, 
including nutrients, hormones, and cytokines (8) and have recently emerged 
as key regulators of metabolism. Particularly, some specific miRNAs in 
mitochondria, often referred as mitomiRs, are crucially involved in regulating 
mitochondrial metabolism, morphology and biogenesis, by modulating 
mitochondrial proteins encoded by nuclear genes. 
Moreover, it has also been reported that the extracellular vesicles - known as 
exosomes - represent a vital communication between different cell types: 
carrying information to reprogram the recipient cells, miRNAs can facilitate 
the crosstalk between cancer and stromal cells in the tumor 
microenvironment, thus favoring tumor progression at all levels and 
perspectives (9).  
Since important cellular signaling pathways are mediated by mitochondria, 
both in normal and transformed cells, an increasing number of human 
diseases is now correlated with morphological and functional changes 
occurring in these important organelles, including neurodegenerative 
diseases and cancer (10). For these reasons, research over the last decades 
largely focused on mitochondrial studies, in order to fully understand their 
implications in malignant progression and dissemination and, hopefully, to 
find new therapeutic approaches for severe malignancies.  
 
1.1- Mitochondria 
Mitochondria are key organelles of nearly all eukaryotic cells, including 
plants, animals, fungi and protists (11). 
Large enough to be observed with a light microscope, the first observations 
of intracellular structure, probably representing mitochondria, date to the 
1840s (e.g. Henle 1841; Aubert, 1852; Flemming 1882, among others). 
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Figure 1: Representation of “Bioblasts” 
observed by Richard Altmann.  
(from Die Elementarorganismen, 1890) 
 In his book Die 
Elementarorganismen of 1890, 
Richard Altmann (1852-1900) 
referred to those “bioblasts” 
he observed using a special 
staining technique with 
fuchsine (Figure 1), as 
“elementary organisms” that 
secreted various cell 
substances, carrying out vital 
functions for the cells (12).  
Comparing them to free-living bacteria, Altmann suggested that 
mitochondria were originally prokaryotic cells, that implemented oxidative 
mechanisms in eukaryotic cells. Nevertheless, his theory was rejected by his 
contemporaries, and the origin of these organelles has been long debated. 
However, based on similarities between mitochondria and bacteria, several 
decades later Altmann’s idea of symbiotic origin of mitochondria was 
accepted, and it is nowadays the most accredited. Further confirmation of 
this view is supported by the analysis of the gene sequences of mtDNA and 
the genome of Rickettsia Prowazekii, etiological agent of typhus, suggesting 
that mitochondria existing today derive from an ancestor of R. Prowazekii, as 
a result of an endosymbiothic single event (13). 
The term “mitochondrion” was introduced in 1898 by Carl Benda, stemming 
from the Greek “mitos” (thread) and “chondros” (granule), that reflect the 
appearance of the organelles when observed, according to cellular 
requirements. Actually, these organelles are specialized structures that play a 
pivotal role in cell metabolism: often described as the “powerhouse of the cell” 
(14), they convert oxygen and nutrients into adenosine triphosphate (ATP), 
which is then used as a source of chemical energy for the cells (15). Being the 
chemical connection between catabolism and anabolism, ATP is a high 
energy compound required for many cellular processes, like muscle 
contraction, cell migration, secretion, and the maintenance of the ion 
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gradients that underlie membrane excitability (16).  
In addition, mitochondria have an essential role in calcium homeostasis, in 
free radical signaling (17), and they are fundamental to cell life and death, as 
they harbor both pro- and anti-apoptotic proteins (18). Furthermore, they 
control cell cycle and cell growth, they may play a role in the aging process 
and are also implicated in several human diseases, including mitochondrial 
disorders and cardiac dysfunctions (19). 
 
1.1.1- Mitochondrial structure 
Mitochondria can be seen in the light microscope, but their detailed internal 
structure (Figure 2, B) is only revealed by electron microscopy (Figure 2, A).  
 
 
Figure 2: Mitochondrial structure.  
(A) Electron microscopy of a mitochondrion (B) Schematic representation of a 
mitochondrion. 
 
As shown in the image, they are pleyomorphic and dynamic organelles, that 
reflect the cell type and the functional state of the tissue of origin. Indeed, 
according to the energetic demand of the cell, number and size of 
mitochondria vary widely, with a diameter ranging from 0.5  to 1.0  µm. 
Moreover, a recent study showed that mitochondria are functionally 
heterogeneous, thus resulting in a wide range of morphologies: different 
areas of the cytoplasm may, therefore, present subpopulations of specialized 
mitochondria in a different functional status, characterized by granular or 
rod-like aspect (20). 
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Despite their plasticity, all mitochondria are double-membrane-systems, 
including two phospholipid bilayers with embedded proteins that define four 
compartments, where different metabolic processes take place: the 
mitochondrial outer membrane (MOM), the intermembrane space, the 
mitochondrial inner membrane (MIM) and the matrix, enclosed by the inner 
membrane (21). 
1.1.1.1- MOM 
The outer mitochondrial membrane is around 6-7 nm tick and encloses the 
entire organelle. MOM is porous and barely selective to ions and other small 
molecules, therefore no membrane potential is registered across the outer 
membrane. Proteins localized in the MOM are integral membrane proteins 
involved in solute exchange between the cytosol and intermembrane space, 
protein import into mitochondria, docking sites for cytosolic proteins, and 
uptake of activated fatty acids into the mitochondria.  
This membrane has a protein-to-phospholipid ratio close to 4:6, and contains 
large number of integral proteins, such as porins, forming channels to allow 
the diffusion of molecules less than 5000 Da, and translocases.  
1.1.1.2- Intermembrane Space 
The equivalent of the periplasm in the bacterial ancestors of mitochondria is 
the intermembrane space. There, concentration of small molecules - such as 
ions and sugars - is the same as in cytosol, because of the outer membrane 
permeability.  
The protein content of this space is much lower than the matrix (about 6% of 
the total mitochondrial protein). Moreover, protein composition of the 
intermembrane space differs from cytosol and matrix, partially due to the 
specific amino acid sequences needed to cross the outer as well as the inner 
membrane. In this area, the main protein is cytochrome c, which is involved 
in cellular respiration and apoptosis. Other potential apoptotic inducers are 
present, as well as enzymes such as adenylate kinase and creatine kinase. 
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1.1.1.3- MIM  
Approximately 21% of the total mitochondrial protein is localized in the 
MIM; in contrast to the MOM, it has a high protein-to-phospholipid ratio and 
is rich in cardiolipin, which is important to stabilize the respiratory chain 
supercomplexes (22). Also, the MIM is highly impermeable to ions and all 
anidrous molecules, a critical property for the maintenance of the proton 
gradient that supports the oxidative phosphorylation. Thus, solutes require 
specific transporters to enter or exit the matrix and it also contains the 
translocase of the inner membrane (TIM) complex, which catalyzes the 
import of proteins into the matrix together with the translocase of the outer 
membrane (TOM) complex.  
To note, the inner membrane folds within the matrix (Figure 3) forming a 
series of invaginations called “cristae” that greatly increase the mitochondrial 
membrane surface, and so the number of sites for oxidative phosphorylation. 
These invaginations appear as tubular structures associated in layers, 
forming lamellar cristae of varying dimensions and forms, connected to the 
intermembrane space through small tubular joints (diameter of about 28 
nm), called "cristae junctions" (23).  
The cristae membranes contain the fully assembles complexes of the ETC and 
the ATP synthase (24) and are, therefore, the main site of biological energy 
conversion in all non-photosynthetic eukaryotes.  
 
 These structures 
have an important 
bioenergetic role, 
since they limit the 
passage of 
metabolites and 
expand the 
membrane surface 
for oxidative 
phosphorylation. 
Figure 3: Internal mitochondrial membrane folds 
into the matrix forming invaginations called 
cristae.  At the cristae ridges, the ATP synthases 
(yellow) form a sink for protons (red), while the 
proton pumps of the electron transport chain (green) 
are located in the membrane regions on either side of 
the dimer rows.  
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Moreover, as noted by Hackenbrock, the system of the inner membrane has a 
dynamic structure, reflecting the oxidative capacity of the tissue: 
mitochondria of high energy demand cells, such as muscle cells, contain more 
cristae and the volume of intra-cristal portions increases (25); conversely, 
cristae are less closely stacked in lower energy demand mitochondria, leaving 
more space for the matrix and its biosynthetic enzymes. 
Nonetheless, the mechanisms that lead to their formation are not firmly 
established: recent studies highlighted a possible involvement of the enzyme 
F1Fo-ATP synthase dimers in determining the folding and invagination of the 
internal membrane, but more studies are currently ongoing to further 
elucidate these mechanisms.  
1.1.1.4- Matrix 
The inner mitochondrial membrane delimits the mitochondrial matrix, which 
has a gelatinous consistency due to the high protein concentration (about 
500 mg/ml), as it contains about 2/3 of the total protein in a mitochondrion. 
This area is the site of organellar DNA replication, transcription, protein 
biosynthesis and numerous enzymatic reactions (24). Several metabolic 
processes take place in the mitochondrial matrix, such as the cycle of citric 
acid and oxidation of pyruvate and fatty acids, vitamins and steroid 
hormones biosynthesis, etc. Moreover, it is also implicated in the calcium and 
ROS signaling and contains the mitochondrial DNA (mtDNA), ribosomes and 
other proteins, including those involved in the cell aging and apoptotic 
process (26).  
 
1.1.2- Mitochondrial homeostasis: fission and fusion 
The functional integrity of mitochondria is strictly dependent on the 
molecular dynamics that controls their size and structure. Therefore, a 
sequence of alternative fusion and fission events (Figure 4) guarantee 
morphological and functional homeostasis of the mitochondrial reticulum 
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(27). 
The fusion/fission machineries are modulated in response to changes in the 
metabolic conditions of the cell (28), enabling cells to generate a 
heterogeneous multitude of mitochondria or a highly dynamic tubular 
network, depending on the physiological conditions and on the functional 
state of the cell. Large mitochondrial networks, generated by the fusion of 
more mitochondria (Figure 4, left side), are usually present in cells with 
active metabolism, while quiescent cells mitochondria typically have 
numerous small spheres or short rods (Figure 4, right side), morphologically 
and functionally distinct (29). 
 
 
 
Moreover, fission is involved in the inheritance process and division of 
organelles during cell division, in the release of pro-apoptotic factors from 
the intermembrane space, into the intracellular translocation of organelles 
themselves and in the turnover of damaged organelles. Conversely, fusion is 
important for the complementation of the gene products of the mitochondrial 
DNA in heteroplasmic cells and to counteract the decline of mitochondrial 
function during aging. This process offers the advantage of limiting and 
correct mitochondrial dysfunctions caused by mutations accumulated in the 
Figure 4: Fusion and fission: interlinked processes critical for mitochondrial 
health.  
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mitochondrial proteins. 
1.1.3- Mitochondrial genome 
Mitochondria have their own genetic system and protein translation 
machinery, complete with ribosomes, tRNAs and associated protein factors. 
Nevertheless, in the course of evolution, they have transferred almost all 
their genes for mitochondrial structure, intermediate metabolism, and 
biogenesis, to the nucleus: specifically, the core circuit genes for 
mitochondrial energy generation are encoded by mitochondrial DNA 
(mtDNA), whereas all of the genes for mitochondrial structure, intermediate 
metabolism, and biogenesis are encoded by nuclear DNA (nDNA). 
                  
 
 
 
 
The human mtDNA is a double stranded, closed circular molecule of 16,569 
nucleotides, containing only 37 genes (Figure 5). The two strands of mtDNA 
are differentiated by their nucleotide content, with a guanine-rich strand, 
referred to as the heavy strand (or H-strand), and a cytosine-rich strand, 
referred to as the light strand (or L-strand). Besides the structural genes, 
mtDNA contains the origin of H-strand replication and a control region (CR), 
that encompasses the promoters for both H- and L- strand transcription. 
Figure 5: Human mitochondrial genome. 
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In humans, only 13 mitochondrial proteins are organelle-encoded; 
remarkably, all these polypeptides are hydrophobic subunits of ETC or ATP 
synthase. Along with the core OXPHOS polypeptides, the mtDNA encodes the 
22 tRNA and 12S and 16S rRNA genes for mitochondrial protein synthesis. In 
addition, the mitochondrial genome contains more than 1000 nDNA-encoded 
mitochondrial genes, including the remaining structural subunits of the 
OXPHOS complexes, the structural polypeptides to assemble the 
mitochondrion, the mitochondrial intermediate metabolism proteins, and the 
proteins for mitochondrial biogenesis proteins, as well as the mitochondrial-
specific DNA, RNA polymerases, and the ribosomal proteins (30). 
Unlike nDNA, mtDNAs are maternally inherited and are present in multiple 
copies, depending on the bioenergetic demand of the cell. Moreover, mtDNA 
replicates independently from cell cycle and does not contain noncoding 
sequences among genes, since large mRNA is translated (there are no 
untranslated regions at 5' and 3'). Lastly, the mtDNA has a higher mutation 
rate compared to the nuclear DNA (nDNA): when a mutation arises, it creates 
a mixed population of normal and mutant mtDNAs, a state known as 
heteroplasmy and, at time of cell division, the two types of mtDNAs are 
randomly distributed into the daughter cells, contributing to accumulate 
mtDNA mutations over aging.  
To note, an increase in mutant mtDNA declines the mitochondrial energetic 
function: poor quality mitochondria may enhance cellular oxidative stress, 
generate apoptosis signals and induce cell death. The bioenergetic crisis may 
also be further exacerbated by reactive species damage to glycolytic and 
glutathione-mediated antioxidant pathways. Therefore, selective removal of a 
subset of dysfunctional mitochondria is a needed and highly regulated 
process for mitochondrial quality control and damaged or dysfunctional 
mitochondria are either complemented with an undamaged part of the 
mitochondrial network, by fusion, or sorted out for mitophagy (31). 
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1.1.4- ETC  
The respiratory chain, or electron transport chain, is a well-organized system 
of electron transporters located in the inner mitochondrial membrane. 
Basically, it consists of a series of protein complexes cooperating to generate 
redox reactions, which couples electron transfer between an electron donor 
and an electron acceptor to the transfer of proton H+ across the membrane, 
thus establishing an electrochemical proton gradient (Figure 6). 
The system receives electrons from reducing equivalents NADH 
(nicotinamide adenine dinucleotide) and FADH2, generated by catabolic 
processes, and the electrons are transferred in an exergonic process unto the 
final conversion of molecular oxygen into water. 
 
 
Figure 6: The electron transport chain (ETC).  
A series of compounds in the inner mitochondrial membranes transfer protons from 
electron donors to electron acceptors via redox reactions and couples this transfer 
with transfer of protons (H+) ions across the membrane. 
 
 
The respiratory chain complexes have been studied in great detail for 
decades: there are four transporter protein complexes and two electron 
carriers, named NADH-Q oxidoreductase (complex I), succinate-Q reductase 
(Complex II), Q-cytochrome c oxidoreductase (Complex III) and cytochrome c 
oxidase (complex IV), besides the lipophilic coenzyme Q (or ubiquinone), and 
the hydrophilic cytochrome c (cit c), that diffuse into the mitochondrial 
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membrane. 
Far from being randomly distributed in the membrane, it has been shown 
that the complex I, III and IV are associated together to form supramolecular 
assemblies (32), in a way that is essentially conserved from yeast to humans. 
Actually, studies conducted by Schagger and Pfeiffer on bovine mitochondria 
revealed that the complex I is associated in a fixed stoichiometry with a 
dimer of complex III and that this supercomplex is - in turn - associated with 
a variable number (usually four copies) of complex IV (33). Other 
electrophoretic studies have revealed the existence of supercomplexes in the 
form of respirasome in bacteria (34), fungi (35), higher plants (36), as well as 
in rats (37) and human mitochondria (38).   
Albeit a clear functional role of mitochondrial supercomplexes is not yet 
established, it has been proposed that this supramolecular organization may 
have a functional significance, since their existence would capture the 
electron transfer between the various components of the mitochondrial 
respiratory chain (39). 
1.1.4.1- Complex I: NADH dehydrogenase 
Complex I is an L-shape large enzyme, consisting of a soluble and 
transmembrane part formed by 46 polypeptide chains, with a horizontal arm 
localized in the membrane and a vertical arm that protrudes in the matrix 
(Figure 7). 
 
Figure 7: NADH dehydrogenase (complex I) 
As shown in the figure, the 
process begins with the 
binding of NADH and the 
transfer of its two electrons 
to the prosthetic group of the 
enzyme, flavin 
mononucleotide (FMN), 
which is thus reduced to 
FMNH2.  
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Then, electrons are transferred to a series of Fe-S centers, whose iron ions 
are cyclically converted from the reduced Fe2+ to the oxidized Fe3+ state.  
Eventually, the electrons flow to the coenzyme Q, which is reduced to 
ubiquinol (QH2) and freely diffuses within the membrane towards Complex 
III. To note, the energy released in the electron transfer reaction between 
NADH and quinone is used for pumping four protons from the matrix into the 
crista lumen: this proton flux from the matrix to the intermembrane space is 
the first step to produce a proton gradient across the membrane, necessary 
to synthesize ATP. However, the way in which electron transfer from NADH 
to ubiquinone in complex I is coupled to proton translocation is still 
unknown, and much else remains to be discovered (40) (24). 
1.1.4.2- Complex II: Succinate dehydrogenase 
Complex II, or succinate dehydrogenase, is the only enzymes involved in both 
citric acid cycle and the electron transport chain (41).  
 
 
 
Figure 8: Succinate dehydrogenase (complex II) 
 
Bound to the inner 
mitochondrial membrane, 
facing the matrix (Figure 
8), this enzyme oxidizes 
succinate to fumarate, 
with the reduction of 
ubiquinone to ubiquinol. 
The electron transfer is mediated by a chain of redox centers, including FAD 
and the Fe-S clusters, that connect succinate and ubiquinone sites. However, 
since the complex does not transport protons, the production of ATP is lower 
when compared to the oxidation of NADH by the complex I. 
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1.1.4.3- Coenzyme Q 
The Coenzyme Q or Ubiquinone is a para-benzoquinone, with a side chain in 
position 6, consisting of a variable number of isoprenoid units. Mitochondrial 
CoQ is inserted into the lipid bilayer of the internal membrane, where 
diffuses freely between the respiratory complexes.  
CoQ is the collection point for the electrons from different dehydrogenase 
complexes, receiving electrons from Complexes I and II, as previously 
described, but also from the glycerol 3-phosphate dehydrogenase and ETF-
dehydrogenase. Upon receiving the first electron, ubiquinon (Q) is partially 
reduced to semi-quinon (QH.-), whereas the second electron fully reduced the 
radicalic form to ubiquinol (or hydroquinone, QH2). At this point, ubiquinol 
diffuses across the membrane and transfers electrons to the Complex III, 
being reoxidized to ubiquinone, and diffusing back towards Complex I and II. 
1.1.4.4- Complex III: Complex bc1 
Complex III is a multisubunit transmembrane protein that catalyzes electrons 
transfer from QH2 to the oxidized cytochrome c, while pumping two protons 
in the intermembrane space (Figure 9).  
 
 
Figure 9: bc1 complex (complex III) 
 
This complex contains 
two types of cytochromes, 
containing heme as a 
prosthetic group: 
cytochrome b, having two 
b-type hemes (bL and bH) 
and cytochrome c, having 
one c-type heme (c1). 
Additionally, it contains an iron-sulfur protein with a 2Fe-2S center, called 
Rieske center, in which one of the iron ion is coordinated by two histidines, 
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rather than two cysteines, thus stabilizing the center in its reduced form: this 
increases the reduction potential, so that the complex can easily accept 
electrons from QH2. 
Complex III catalyzes the reduction of cytochrome c, by oxidation of 
coenzyme Q (ubiquinone), together with the concomitant translocation of 
four protons from the mitochondrial matrix to the intermembrane space (Q 
cycle process). Essentially, two QH2 molecules consequentially bind to the 
complex, each one releasing two protons and two electrons, that are driven 
into two different directions. As a result, in the Q cycle two electrons are 
passed to cytochrome c, two protons are consumed from the matrix and four 
protons are released into the intermembrane space, contributing to generate 
the proton gradient across the membrane (42). 
1.1.4.5- Cytochrome c 
The Cytochrome c is a small soluble protein, with a molecular mass of about 
13000 u, consisting of about 100 highly conserved residues. Located in 
proximity of the outer side of the inner mitochondrial membrane - to which 
is bound by electrostatic interactions – this other mobile electron-carrier of 
the respiratory chain transports electrons between the Complex III and 
Complex IV. 
Electrons transferring from complex III to complex IV is related to the 
reversible oxidation of the iron in the heme group (Fe2+-Fe3+): when the 
heme group of cytochrome c accepts an electron from Complex III, 
cytochrome c moves to the Complex IV to donate the electron to a binuclear 
cupric center of this enzyme. 
1.1.4.6- Complex IV: Cytocrome c oxidase 
Finally, complex IV is a large transmembrane protein complex that catalyzes 
the transfer of electrons from each of four cytochrome c molecules and 
transfer them to one molecular oxygen, the last acceptor, that is converted 
into water (Figure 10).  
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The three major subunits (I, II, and III) are encoded by mitochondrial DNA 
and form the enzyme's catalytic core, surrounded by the remaining ten 
subunits, smaller and encoded by the nuclear DNA. 
 
1.1.5- Oxidative phosphorylation 
The majority of ATP in most mammalian cells 
is produced in the inner membrane by the central mitochondrial energy 
transformation system: the oxidative phosphorylation (OXPHOS). Practically, 
substrates oxidation in the ETC generates a proton gradient across the inner 
membrane, over the electron flow through the ETC, and the OXPHOS system 
couples this proton motive force (pmf) with the phosphorylation of ADP in 
ATP. 
Sir Peter D. Mitchell was the pioneer of the so-called chemiosmotic theory, 
proposed in 1961, assuming that the energy released during electron 
transport in the respiratory chain is used to pump protons from the 
mitochondrial matrix to the intermembrane space, thereby creating a 
difference in proton concentration on the two sides of the inner 
mitochondrial membrane. In this way, an electrochemical proton gradient - 
resulting from the difference in pH (ΔpH) - and an electrical gradient (ΔΨm) - 
given by the difference in charge - is established between the two sides of the 
inner mitochondrial membrane. This electromotive force proton pushes the 
 
 
Figure 10: Cytochrome c oxidase 
 (complex IV) 
The bovine enzyme structure was 
deduced by crystallography: with a 
molecular mass of approximately 200 
kDa, it appears as a Y-shaped dimer, 
wherein each monomer consists of 13 
subunits. 
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protons back to the matrix, through the F0 section of ATP synthase (complex 
V of OXPHOS, Figure 11). 
During this flow across the inner membrane, energy is provided for 
adenosine diphosphate (ADP) to combine with inorganic phosphate and form 
ATP (as described in the following section), which is then exchanged by 
cytosolic ADP via the adenine nucleotide translocators (ANTs), to let the ETC 
continuing its cycle (in absence of ADP and Pi, the electron flux through the 
ETC would be otherwise interrupted). 
 
 
 
Mitochondrial OXPHOS powers a wide range of energy-based cellular 
functions, including maintaining the oxidation–reduction balance of the cell, 
generating a capacitance across the mitochondrial inner membrane, 
converting this potential energy into chemical energy, in the form of ATP, 
using the mitochondrial capacity to import calcium and modulate cellular and 
mitochondrial reactions, producing reactive oxygen species (ROS) as signal 
transduction molecules, and initiating cell death by activation of the 
mitochondrial permeability transition pore (mtPTP) to destroy those cells 
with defective mitochondrial energy production. 
Figure 11: Oxidative phosphorylation (OXPHOS) in mitochondria. 
Complex I (NADH/ubiquinone oxidoreductase), II (succinate dehydrogenase), III 
(cytochcrome c reductase), IV (cytochrome c oxydase) and the mitochondrial ATP 
synthase (also known as complex V, tan) work together in oxidative phosphorylation to 
harness energy for the cell. Complexes I, III and IV pump protons across the cristae 
membrane, creating the proton gradient that drives ATP synthesis.  
 Simona Barbato Pag. 25 
 
1.1.6- ATP synthase: structure and function 
The F1Fo-ATPase is a transmembrane enzyme complex found in the plasma 
membranes of bacteria, in the thylakoid membranes of chloroplasts and in 
the inner membranes of mitochondria.  
 
Figure 12: F1Fo ATP synthase 
The architecture of the enzyme is 
shown in Figure 12: it is a large 
mushroom-shaped asymmetric 
protein complex, with a total mass of 
about 550-650 kDa.  Specifically, it 
consists of two main structural 
sections, distinct both structurally 
and functionally, linked by a central 
and a peripheral stalk  (43).  
The globular catalytic F1 domain is an assembly of five globular proteins, in a 
stoichiometry of three copies of each subunit α and β, and one of γ, δ and ε. 
The γ subunit and the associated δ and ε of F1 constitute the central stalk of 
the complex, being part of the γ-subunit completely enveloped in the α3β3 
domain, while the rest protrudes to form a sort of “foot” that firmly attaches 
that complex to the cylindrical structure Fo.  
The proton-translocating membrane-embedded Fo portion, instead, consists 
of a subunit c-ring, plus one copy each of subunits a, b, c, d, F6 and the 
oligomycin sensitivity-conferring protein (OSCP). Subunits b, d, F6 and OSCP, 
form the peripheral stalk, an elongated and largely α-helical structure that 
extends from the Fo membrane domain to the topmost extremity of the F1-
domain, where it binds to the N-terminal region of an α –subunit (44). Its α-
helical N-terminal domain provides the binding site for the N-terminal region 
of one of the three α-subunits of F1, whereas its C-terminal domain interacts 
with the C-terminal region of the b-subunit and with Fo (45) 
The enzyme catalyzes the synthesis of adenosine triphosphate (ATP) from 
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adenosine phosphate (ADP) and inorganic phosphate (Pi), through the 
“binding-change” mechanism ( 
Figure 13), first proposed by the Nobel prize-winner Paul Delos Boyer (46).  
 
 
 
Figure 13: Binding-change mechanism proposed by P.D. Boyer in 1975.  
The binding-change mechanism as seen from the top of the F1 complex. There are three 
catalytic sites in three different conformations: loose, open, and tight. Substrate (ADP + 
Pi) initially binds to the open site and is converted to ATP at the tight site. A 120° 
rotation of the γ subunit causes a conformational change, resulting in a change in the 
formation of the sites. As a result, ATP is released from the enzyme. Then, a second 
120° rotation occurs, substrate again binds to the open site, and another ATP is 
synthesized at the tight site 
 
According to Boyer’s theory, each of the three β subunits switches 
cooperatively through conformations in which ADP and Pi bind, ATP is 
formed and released (O: Open, T: Tight, L: loose). These transitions are 
accomplished by rotational catalysis driven by the rotating inner core of the 
enzyme, which is in turn driven by the protons crossing the mitochondrial 
membrane (47).  
Being a reversible nanomotor, the enzyme can also catalyze the opposite 
reaction. Indeed, when the membrane potential collapses the enzyme 
hydrolyzes ATP to pump protons through the membrane, in order to restore 
ΔΨm. Since depletion of ATP precipitates cell death, wasteful hydrolysis of 
ATP must be prevented when respiration is compromised: for this reason, 
the action of the enzyme need to be precisely regulated.  
 
1.1.6.1- Regulation of ATP synthase 
As mentioned above, the main function of F1Fo-ATPase is the synthesis of 
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ATP. Given the intrinsic characteristics of the ATP synthase, the directionality 
of the enzymatic reaction is determined by the balance between the energy 
supplied by the phosphorylation potential and the Δψm: the removal of ATP 
by ANT in normal conditions ensures relatively low phosphorylation 
potential and high ΔΨm, thus facilitating the synthesis of ATP. However, when 
the mitochondrial homeostasis is compromised, the decrease in ΔΨm, along 
with the reversion ANT - that starts importing glycolytic ATP - promotes the 
hydrolysis of ATP to restore physiological levels of ΔΨm.  
In many species, like bacteria, the reverse reaction of ATP hydrolysis is vitally 
important: when neither respiratory nor photosynthetic chains can generate 
pmf, the ATP synthase can work as a proton pump, at the expense of ATP, 
supporting important cellular functions, including flagella motility, or 
nutrients transmembrane transport. Nevertheless, the ATP hydrolysis 
activity is mostly a potential danger to living cells: when the fall of ΔΨm is 
extreme, the only effect is the gradual depletion of cellular ATP, that leads to 
cell death. For this reason, futile ATP wasting must be prevented, as ensured 
by a precisely regulation of the enzyme activity through several mechanisms, 
like transcription factors, modulation of the citric acid cycle, as well as the 
regulation of the electron transport chain, the inhibition of ADP or ANT and 
proteins regulation, including the inhibitory factor 1 (IF1) (48). 
Although recent evidence has also suggested that the oncoprotein Bcl-XL 
interacts with the F1Fo-ATPsynthase (49), IF1 is the only molecular regulator 
of the enzyme characterized both biochemically and functionally. 
 
1.1.6.2- Dimerization of ATP 
The structure of several subcomplexes of ATP synthase has been determined 
by X-ray crystallography, revealing that many organisms display extensive 
rows of dimers along the highly curved cristae ridges in mammals, plants, 
and fungi. Moreover, electron cryotomography of mitochondria and 
mitochondrial membranes from six different species showed that the two F1 
subcomplexes within each dimer are consistently 28 nm apart, whereas the 
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distance between adjacent dimers along the rows was variable, indicating 
that the dimers do not interact directly (50).  
Oligomeric state of ATP synthase has been suggested to determine the 
arrangement of mitochondrial cristae, therefore determining mitochondrial 
morphology. In addition, it has been  proposed that an alteration in pH occurs 
in the curvature of the inner mitochondrial membrane, suggesting that this 
proton trap is able to ensure appropriate ATP synthesis when the availability 
of protons is limited (51). However, the mechanisms underlying this 
supramolecular organization and the functional role of this assembly are not 
yet definitively established.  
The first appearance of oligomerization dates back to 1989, when Allen (52) 
suggested that the dimeric form is the starting point for the construction of 
oligomeric form. In his work, Allen proposed that the dimers form a rigid 
bow, which promotes the formation of cristae by protruding from the planar 
surface of the mitochondrial membrane, in line with molecular dynamics 
simulations performed by Kuhlbrandt and co-workers, showing that an 
individual ATP synthase dimer causes a marked deformation of the 
surrounding lipid bilayer, inducing a positive, convex curvature in one 
direction and a concave curvature in the perpendicular direction (50). 
Therefore, the dimers seem to be responsible for the formation of the highly 
curved cristae ridges, and an essential element of normal mitochondrial 
morphology.  
To note, more recent studies investigated on the involvement of the inhibitor 
of the ATP synthase, IF1, to form dimers of the enzyme, thereby contributing 
to modify mitochondrial morphology: since the active form of IF1 is a dimer 
with its two N-terminal domains at both sides of the structure, free to 
interact with the F1- ATPase, questions have raised to define whether IF1 
promotes the dimerization of the ATP synthase, or at least stabilizes the 
dimeric form of the complex, but further studies are needed to elucidate this 
association. 
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2- IF1 
In 1963, M.E. Pullman and C.G. Monroy discovered a soluble, heat-stable 
protein in mitochondria from bovine heart, that inhibits the ATP hydrolase 
activity of the F1F0-ATPase (53). This protein is activated in response to 
acidification of the mitochondrial matrix, which usually accompanies the 
inhibition of mitochondrial respiration (i.e. during hypoxia/ischaemia), with 
the consequential collapse of ΔΨm and the reversal of F1Fo-ATP (54). 
However, as soon as the mitochondrial inner membrane gets re-energized 
and the proton gradient is rebuilt across the membrane, the enzyme restarts 
to catalyze the ATP synthesis and the inhibitor is rejected, acting – therefore 
– as an unidirectional valve (19). 
Highly conserved throughout evolution, the mammalian IF1 is a small, basic 
protein of about 10 kDa, encoded by the nuclear gene ATPIF1. This 
propolypeptide is α-helical along most of its length and contains 106–109 
amino acids, depending on the species of origin, including a 25-residues 
mitochondrial targeting pre-sequence (that is cleaved within the 
mitochondria to form the mature IF1 of 84 aminoacids) and the inhibitory 
portion from residues 48 to 70 (bovine numeration), with homologues in 
birds, nematodes, yeasts and plants mitochondria.  
This latter domain is highly conserved throughout the species, so that the 
inhibitory function of the protein is maintained across F1Fo-ATPases of 
different species, albeit with different efficacy (55). More importantly, this 
domain is sensitive to pH, and is thus responsible for the molecular switching 
between the active form, in acid conditions, and the inactive form, above 
neutrality (Figure 14). In alkaline conditions, indeed, inactive tetramers or 
higher oligomers are held together by antiparallel coiled-coils in the N-
terminal regions, masking the inhibitory regions (56). Conversely, when pH 
is low (i.e. 6.7 or below), residues 48 to 56 are involved in the formation of an 
antiparallel double-stranded coiled-coil region between two IF1 molecules, to 
generate the active inhibitory dimer that binds two F1 domains of the 
enzyme, further stabilized by complimentary hydrophobic interactions 
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between the two helices.  
 
 
 
 
 
As proposed by Walker, the inhibitor binds to the soluble F1 domain, via the 
most accessible of the three catalytic interfaces (between the αE- and βE-
subunits, where no nucleotide is bound) in the presence of Mg2+ and ATP. 
When the first 120° rotational step occurs, the βE-αE interface is converted to 
the βTP-αTP interface; then, a second 120° rotational step follows, and the 
inhibitor can enter its binding site in the hydrophobic pocket in the adjacent 
β-subunit and augment the binding of the inhibitor to F1-ATPase, with further 
interactions taking place between the γ-subunit and the shorter α-helix 
(residues 14–18 of IF1) and the region linking it to the longer α-helix 
(residues 19–21), therefore inhibiting other rotations (58).  
However, upon the reversal of rotation - from the counterclockwise direction 
that accompanies ATP hydrolysis, to the clockwise direction required for ATP 
synthesis - the interactions of IF1 with the F1-domain of the inhibited enzyme 
are destabilized, leading to the ejection of the inhibitor from the catalytic 
interface.  
Figure 14: Inactive (a) and active (b) structures of IF1  (from (57)) 
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Long investigated for its ability to inhibit the hydrolytic activity of the 
enzyme F1Fo-ATPase, IF1 is now examined for other potential roles, with a 
large attention given to its possible contribute in pathophysiological 
conditions. Indeed, the homodimeric conformation binds two F1 domains 
simultaneously, encouraging many hypothesis on the involvement of IF1 in 
defining the oligomeric state of the F1Fo-ATPsynthase – thus influencing the 
activity of the enzyme – and, far beyond, in remodeling mito-ultrastructure 
and morphology of mitochondria, leading to the formation of mitochondrial 
cristae.  
More intriguingly, several groups recently focused on the overexpression of 
this protein found in many human carcinomas, prompting interesting 
speculations about the role of IF1 in tumor metabolism. Furthermore, the 
protein has been likely related to an increase malignancy of tumors, by 
helping cells to survive in hostile conditions, protecting cancer cells from 
death, by escaping apoptosis, and increasing tumor ability for invasion and 
metastasis.  
 
Figure 15: The inhibitory binding of IF1 to the catalytic interface of the enzyme. 
The two schemes differ by ADP being bound to the βDP-subunit in (A) and ATP in (B). 
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2.1- IF1 in dimerization 
The role of IF1 in the oligomerization of the ATP synthase is much debated. 
Many studies in the literature propose that IF1 contributes to stabilize the 
dimeric form of the F1F0-ATPase, since the active form simultaneously binds 
two F1 portions, consequently promoting the formation of mitochondrial 
cristae and, hence, the ultrastructure of mitochondrial morphology (59).  
Garcia and co-workers (60) first highlighted the possible involvement of the 
inhibitor in the dimerization of the ATP synthase and in the biogenesis of the 
mitochondrial cristae, reporting an increase in the dimer/monomer ratio 
when increasing the expression of IF1, whereas the silencing of the inhibitor 
resulted in a switched ratio, in favor of the monomeric form of the enzyme.  
Consistently, a number of studies by Campanella and co-workers reported 
that IF1 increases F1Fo-ATPsynthase activity in respiring mitochondria, 
promoting its dimerization and increasing the density of mitochondrial 
cristae and mitochondrial volume fraction (59) (61). However, this ideas 
have been rejected by others, reporting that the organization of the ATP 
synthase in the dimeric form was independent from the inhibitor (62). More 
studies are therefore needed to elucidate the influence of the inhibitor to the 
activity of the F1Fo-ATPase and to define mitochondrial content.  
 
2.1- IF1 and ROS 
As a byproduct of OXPHOS, mitochondria generate much of the cellular ROS, 
highly unstable compounds with an unpaired electron in their chemical 
structure. One of the major compounds in mitochondria is the superoxide 
radical: specifically, complexes I and III likely have the primary responsibility 
for its generation during the electrons transfer through their redox centers.  
ROS concentration inside the cell must be finely controlled, since small 
amount can mediate different cellular signaling pathways, whilst higher 
concentrations can damage cell structures, enzymes, nucleic acids and lipids, 
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besides inducing mitogenic pathways and stimulating carcinogenesis. 
Although under physiological conditions the production of ROS is well 
balanced by cellular antioxidant mechanisms, different diseases can alter this 
balance, ultimately triggering the mechanisms of apoptosis and cell death.  
By preventing the production of ROS, IF1 may protect cancer cells from ROS-
mediated apoptosis. Moreover, it was recently reported that  autophagy was 
dramatically increased in the IF1-siRNA treated cells, but this phenomenon 
was prevented by the superoxide dismutase mimetic, indicating that the 
inhibitor may limit mitochondrial ROS generation, therefore reducing 
autophagy. In this view, variations in IF1 expression level may therefore play 
a significant role in defining both resting rates of ROS generation and cellular 
mitochondrial content (63). However, recent evidence have also shown that 
ROS play a key role as a messenger in normal cell signal transduction and cell 
cycling and the mitochondrial ATPase inhibitory factor 1 has been described 
as a ROS-mediated retrograde prosurvival and proliferative response 
activator (64). 
 
2.2- IF1 in cancer 
Energy metabolism, apoptosis, as well as the production of reactive oxygen 
species (ROS) and important cellular signaling pathways are mediated by 
mitochondria, which play a crucial role in cell physiology. For this reason, an 
increasing number of human diseases is now correlated with morphological 
and functional changes occurring in these important organelles, including 
neurodegenerative diseases and cancer (10). Numerous studies conducted in 
the last decade, indeed, clearly indicate that mitochondrial dysfunctions are 
one of the most recurrent characteristics in cancer cells, as proven by 
microscopic and genetic alterations, as well as by biochemical and molecular 
analysis. 
Particularly, in recent years, it has been rediscovered the importance of 
energy metabolism in cancer biology: oxidative phosphorylation (OXPHOS) 
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covers almost the whole of the energy demand of many differentiated cells, 
while many evidence report an increase of the consumption of glucose in the 
neoplastic cells (Warburg effect), therefore suggesting that transformed cells 
experience a metabolic reprogramming, resulting in a predominantly 
glycolytic phenotype. 
As IF1 is upregulated in a large proportion of human cancers, this protein is 
currently under investigation for its involvement in cellular energy 
metabolism and oncogenesis. Actually, the expression of the protein varies 
widely in different normal human tissues, but many data reported its 
increased expression in many types of cancer (65) (66), along with a 
decreased OXPHOS activity, mitochondrial hyperpolarization and 
simultaneous increase of glycolysis. In this view, the over-expression of IF1 in 
human tumors may contribute to the onset the peculiar energy metabolism 
of mitochondria in cancer, acting as a molecular switch for a metabolic shift 
from oxidative phosphorylation to glycolysis phenotype that characterizes 
cancer cells.  
Moreover, considering that most of the tumors rely on a poor vascularity, 
with highly variations of oxygen levels from the perivascular regions to the 
anoxic necrotic centers, the IF1 over-expression in several human cancers 
could play an important role in the pathology of tissue ischemia and tumor 
growth, by helping cells to conserve ATP. Actually, when the cells are 
deprived of oxygen and glucose, cells with a silenced-expression of the F1Fo--
ATPase inhibitor rapidly deplete ATP and dye more rapidly than control 
ones, indicating the role of IF1 in maintaining the concentration of ATP in 
energy crisis situations. However, the contribution of this protein in tumor 
mitochondrial bioenergetics is still debated and data in the literature are 
controversial.  
A recent study (64) also reported that IF1 leads to chemotherapy resistance 
and promotes the proliferation of cancerous cells via signaling pathways 
mediated by the transcription factor NFkB. In addition, the inhibitor protein 
has been explored in relation to the progression of apoptosis: IF1 expression 
has been reported to serves as a checkpoint for the release of cytochrome c 
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and, hence, the completion of the apoptotic program. Considering also its 
possible role in inducing dimerization of the ATP synthase, the inhibitor of 
the enzyme could play a key role in avoiding the fragmentation of the 
mitochondrial network and the release of cytochrome c from the 
mitochondrial cristae, further protecting cells from apoptotic death (27).  
However, little is still known on the effects associated with IF1 and the 
hypothesis proposed are highly controversial at present, underlying the 
emergent need of a deeper investigation over the role of this protein, in order 
to define how IF1 can affect mitochondrial activity and, more intriguingly, 
how this protein can contribute to cancer cell survival and progression, 
escape apoptosis and affect cancer cell metabolism. 
 
3- Altered pathways in cancer 
As reported above, alterations in oncogenes, tumor-suppressor genes and 
stability genes are responsible for tumorigenesis. Mammalian cells, however, 
have multiple safeguards to protect them against cancer gene mutations, and 
only when several genes are defective an invasive cancer can develop.  
Albeit all genes are potentially affected by the resultant increased rate of 
mutations, alterations in cancer genes that directly control cell cycle and cell 
proliferation can affect net cell growth, thereby conferring a selective growth 
advantage to the mutant cell. For example, the oncogene cdk4, cyclin D1 (67), 
and the tumor suppressor gene Rb (68) and p16 can respectively be activated 
or inactivated by mutations. In addition, others pathways are frequently 
involved in many tumor types, including developmental pathways involving 
glioma-associated oncogenes (GLI), or hypoxia-inducible transcription factor 
(HIF)-1 (28), among others, eventually resulting in uncontrolled rate of 
proliferation, cancer development and progression (69).  
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3.1- SHH pathway 
Normal development during embryogenesis requires a number of complex 
signaling cascades, including the Hedgehog (Hh) pathway, a key mediator of 
many fundamental processes in vertebrate embryonic development that 
controls cell fate, patterning, proliferation, survival and differentiation of 
many different regions.  
First described in 1980 by Christiane Nusslein-Volhard and Eric F. 
Wieschaus, (70) in their genetic analysis of the fruit fly Drosophila 
melanogaster, the name Hedgehog (Hh) originates from the short and ‘spiked’ 
phenotype of the cuticle of the Hh mutant Drosophila larvae, which 
resembled the spikes of a hedgehog (71). Although many of the key 
components are conserved in vertebrates, the mammalian Hh signaling 
pathway is incompletely understood and harbors some additional 
components, suggesting that the mechanism of Hh signal transduction have 
evolved differentially after separation of the vertebrate and invertebrate 
lineages, approximately 1 billion years ago (72). Moreover, mammalian Hh 
signaling relies on several compounds involved in the formation of the 
primary cilia - not required in Drosophila – that would act as a “signaling 
center” where the biochemical events of signal transduction take place (73). 
In vertebrates, the canonical Hh pathway contains several key components, 
including Hh glycoproteins Desert Hedgehog (Dhh), Indian Hedgehog (Ihh), 
and Sonic Hedgehog (Shh), three Hh gene homologs discovered in the early 
1990s (74) (75) (76). Hh proteins act as morphogens, controlling multiple 
different developmental processes. Particularly, Dhh and Ihh have been 
shown to play important roles in normal tissue development, being Dhh 
expression largely restricted to gonads, while Ihh is specifically expressed in 
a limited number of tissues, including primitive endoderm (77), and 
prehypertrophic chondrocytes in the growth plates of bones (78). By 
contrast, Shh is the most potent of these ligands and the most widely 
expressed mammalian Hh signaling molecule, inducing cell proliferation in a 
tissue-specific manner: during early vertebrate embryogenesis, it is 
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expressed in midline tissues such as the node, notochord and floor plate 
controls patterning of the left-right and dorso-ventral axes of the embryo 
(79); later in organogenesis, Shh affects development of most epithelial 
tissues, and in adults it remains active, regulating tissue homeostasis, 
continuous renewal and stem cells maintenance, as well as preserving tissue 
polarity (80).  
In humans, the Hh cascade in the target cell is triggered by the Hh ligand 
binding to the Patched receptor (Ptch), a 12-span transmembrane protein 
that exists as two isoforms in vertebrates, Ptc1 and Ptc2. In absence of the 
ligand, Ptch inhibits downstream signaling by catalytically inactivation of the 
seven-transmembrane-span-receptor-like protein, Smoothened (Smo) (81), 
affecting its localization to the cell surface, or by eliciting endogenous Smo 
agonists to prevent its binding. Conversely, upon secretion of Shh 
glycoproteins, Ptch is inactivated and Smo is activated, resulting in the 
transduction of the Hh signaling to the cytoplasm and the nuclear localization 
of the terminal effectors of the Shh signaling, the glioma-associated (GLI) 
transcription factors.  
In vertebrates, the GLI factors exist as three separate zinc-finger proteins: 
GLI1 and GLI2, functioning as transcriptional activators, and GLI3 as a 
transcriptional repressor (82). Once in the nucleus, GLI transcription factors 
can activate target genes involved in HH pathway feedback (e.g., GLI1, Ptc1), 
proliferation (e.g., Cyclin-D1, MYC), apoptosis (e.g., Bcl-2), angiogenesis (e.g., 
ANG1/2), epithelial-to-mesenchymal transition (e.g., SNAIL), and stem cell 
self-renewal (e.g., NANOG, SOX2) (83) (84) (85).  
Moreover, genetic evidence from Drosophila indicate that the full activation 
of the pathway in response to Hh stimuli also requires the Fu protein kinase, 
which blocks the negative influence of the Suppressor of Fused (SUFU). 
Unlike the fruit fly, in which this latter component has only a minor role, 
mammalian Hh signaling critically depends on SUFU, that negatively 
regulates the pathway: in the absence of ligand, SUFU directly binds to GLI 
transcription factors and anchors them in the cytoplasm, thus facilitating 
their degradation and, more importantly, inhibiting Shh pathway signaling by 
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preventing the activation of GLI target  genes. In addition, SUFU has also been 
shown to form a repressor complex leading to interaction with DNA-bound 
GLI1 and suppression of GLI1-induced gene expression (86).  
 
 
 
 
Thus far, it is important to note that Hh signaling is crucial in development, as 
evinced by the dramatic consequences in human fetuses with inherited or 
sporadic mutations in the Shh signaling pathway, resulting in a number of 
human birth defects, like holoprosencephaly, microencephaly, cyclopia, 
absent nose or cleft palate (87) (88). Moreover, abnormal activation of the 
Shh pathway has been recently shown to affect tumorigenesis, apoptosis, 
migration, and angiogenesis of various cancer that usually originate from 
endoderm, enclosing gastric, pancreatic, colon, lung, prostate, and 
Figure 16: Shh Pathway in mammals. 
The interaction between Shh and Ptch1 leads to the ciliary localization of Smo, which 
is otherwise inhibited by Ptch1. A Gli-Sufu complex is also localized to the cilium and it 
is believed that Gli proteins are proteolytically processed in the absence of Shh. 
Conversely, in the presence of Shh, activated Smo promotes the dissociation of Gli 
proteins from Sufu and turns Gli proteins into transcriptional activators. 
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hepatocellular cancer (89). Furthermore, Hh might also promote 
tumorigenesis or tumor growth acceleration in a wide variety of tissues, by 
signaling in a paracrine manner from the tumor to the surrounding stroma, 
or in cancer stem cells (CSCs).  
 
3.1.1- Shh pathway and Melanoma 
In recent years, it has become increasingly clear that abnormal Shh signaling 
can lead to cancer: the role of deregulated Shh signaling in cancer was first 
characterized by studies of basal cell nevus syndrome, also known as Gorlin 
syndrome, an autosomal dominant disorder leading to craniofacial and 
skeletal abnormalities, together with a notably increased risk of advanced 
basal cell carcinoma and medulloblastoma (90). Specifically, it has been 
proposed that a ligand-independent Hh pathway-activating mutation was 
responsible for aberrant Shh pathway activity, leading to the development of 
BCCs and medulloblastomas (91). Alternatively, it has been observed that 
Shh pathway can be altered in a ligand-dependent manner, either with 
autocrine or paracrine signaling, in multiple tumor types including lung (92), 
pancreatic, colorectal (93), prostate (94) metastatic carcinomas, and gliomas 
(95).  
In this sense, it is quite clear that tumor growth and metastatic dissemination 
of tumor cells strictly rely on reciprocal interactions between cancer cells 
and the surrounding stroma (96). As revealed by studies in epithelial cancers, 
indeed, tumor cells secrete Shh ligand, that stimulates production of 
secondary growth factors driving tumor angiogenesis, tumor cell 
proliferation, and survival (97). Thus, identifying novel mechanisms critically 
regulating tumor–stroma interactions may be therapeutically relevant in 
aggressive types of cancer, like cutaneous melanoma, that requires secretion 
of growth factors and cytokines to grow and disseminate (98).  
Melanoma represents approximately 4% of human cutaneous neoplasm (99), 
especially common among Caucasians, with a rapidly increasing incidence in 
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Oceania, North America, Europe, South Africa and Latin America (100). 
Despite this low rate of incidence with respect to other types of cancer, 
however, it is a highly aggressive and poor prognosis tumor, that yet 
accounts for almost 80% of deaths related to skin cancer (101).   
Research over the last decade showed that multiple genetic alterations play a 
role during the progression of this complex genetic disease: among these, 
activating mutations in the oncogenes BRAF and NRAS - ultimately involved 
in cell growth, proliferation and survival - are a genetic hallmark of 
melanoma, being present in 70% and 15% of melanomas, respectively.  As a 
result, these mutations can cause unintended and overactive signaling inside 
the cell (e.g. in the absence of incoming signals), leading to increased and 
uncontrolled cell proliferation and resistance to apoptosis (102). More in 
detail, studies on melanoma revealed that over 50% of metastatic melanomas 
harbor the BRAF(V600E) point mutation (103), with a substitution in 
position 600 of a glutammate with a valine, that cause a constitutively active 
protein serine kinase, thus sustaining the BRAF→MEK1/2→ERK1/2 MAP 
kinase pathway, critically implicated in the regulation of gene expression, as 
well as cell proliferation and survival, all involved in the initiation and 
progression of melanoma (104).  
Since the discovery of BRAF(V600E) mutation in melanoma, scientists and 
clinicians have learned much about mechanisms that underlie melanoma 
origin and progression, but many questions remain unanswered, with 
attention given to other developmental pathways that may be involved in 
both formation and progression of the disease. Interestingly, a recent study 
suggested that Shh-GLI activity could be a basal, yet essential, requirement in 
melanoma: Stecca et al. previously reported that GLI1, a direct GLI2 target, is 
required for normal melanocyte proliferation as well as for growth and 
metastasis of melanoma cells. The acquisition of oncogenic RTK-RAS-RAF-
MEK and/or AKT signaling could result in cell-intrinsic enhancements of 
GLI1 transcriptional activity, and such increases may then participate in 
disease progression (105).  
Additionally, the Hh pathway may induce PDGFRα up-regulation (106), thus 
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helping melanoma progression in a positive autocrine/paracrine feedback on 
GLI1 function. Moreover, GLI2 has been found overexpressed in human 
melanoma and associated with melanoma cell invasion, matrix 
metalloproteinase (MMP) secretion, expression of E-cadherin, and metastasis 
to bone (107), indicating that GLI2 could be a common target of the 
developmental machinery and a progression factor in melanoma. 
However, although progress has been made in understanding the genetics of 
the molecular events underlying melanoma oncogenesis, the clinical 
challenge remains enormous: molecules that inhibit mitogen-activated 
protein kinase pathway–associated kinases, like BRAF and MEK, as well as 
Shh inhibitors, have shown only limited efficacy in the treatment of 
metastatic melanoma (108). Thus, a deeper understanding of the cross talk 
between signaling networks and the complexity of melanoma progression 
should lead to more effective therapy.  
 
3.2- Melanoma therapy and Drug resistance 
Metastatic melanoma is a rapidly progressing disease with an 8-month 
median overall survival and a 25% 1-year survival rate. The majority of 
melanoma lesions are diagnosed early and are mostly excised and curable, 
with excision and lymph node resection if involved, but advanced melanomas 
are really hard to cure and current therapies include chemotherapy, 
radiotherapy, immunotherapy, or a combination of them (109). Moreover, 
many clinical trials are currently ongoing, aiming to improve treatments and 
reduce side effects with the help of target therapies, in order to mark only the 
typical genetic hallmarks of melanoma cells rather than any quickly dividing 
cell. 
Development of therapeutics for the canonical Shh signaling pathway has 
primarily focused on targeting Smo, through natural and synthetic 
antagonists, with varying degrees of success. Among these, one of the first 
investigated was the natural steroidal alkaloid cyclopamine, followed by a 
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number of derivatives, in the hopes of increasing specificity and 
pharmacological potency. In addition, GLI1 was singled out as a therapeutic 
target - as it is the most characterized GLI transcription factor associated 
with activation of Shh target genes – and GLI2 was also considered a 
potential mark, leading to a rapid expansion of GLI small-molecule inhibitors, 
attempting to provide the basis for other therapeutic approaches. However, 
Shh antagonists only have little effect on melanoma cells: likely because of 
deregulation of this stimulatory signaling mechanism, tumor cells often 
become Shh independent, and endogenous or exogenous Shh has no effect on 
melanoma growth and migration.  
Likewise, target therapies over the last decade have been deeply focused on 
targeting the BRAF signaling cascade, by blocking the constitutive activation 
of this oncogene caused by the typical BRAF gene mutations. On this side, a 
number of papers reported the efficacy of the BRAF inhibitor (vemurafenib) - 
as well as other inhibitors in its class - in inducing tumor regression in more 
than 50% of the patients with BRAF(V600E) mutated metastatic melanoma. 
For these reasons, in 2011 the FDA approved vemurafenib as the major 
breakthrough in the treatment of these types of melanoma, with improved  
progression free and overall survival of a large number of patients supported 
by many clinical trials. However, monotherapy regimens with these new 
pharmaceuticals are hampered by the emergence of dose-limiting toxicity 
and secondary cancers: although some of these concerns are addressed by 
the combination therapies, complete responses to these targeted therapies 
(e.g., vemurafenib) are only observed in a small percentage of patients, as a 
consequence of intrinsic BRAF-I resistance. More importantly,  the median 
time to disease progression is really short, since patients acquire resistance 
to therapy and tumor recurs much more aggressively, with the inevitable 
death of patients.   
As tumor is continuously evolving during its progression, it is important to 
note that cancer cells have a continuous turnover in this process, allowing an 
ongoing selection of the fittest cells, able to escape different mechanisms of 
apoptosis, induced by their microenvironment, and yet to proliferate widely, 
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regardless possible hostile conditions prompted by the treatment. In this 
view, resistance to therapy might be considered as a consequence of 
reduction of several distinct cell death mechanisms, as well as from an 
increased ability to regenerate. Thus far, mechanisms by which tumor cells 
resist the action of anticancer drugs have been deeply investigated in the last 
decades: cancer drug resistance, either intrinsic or acquired with therapy, 
encompasses various mechanisms, including altered expression 
of drug influx/efflux transporters, altered role of DNA repair and impairment 
of apoptosis, as well as epigenomics and altered levels of microRNAs, that 
may lead to alterations in upstream or downstream effectors, among others.  
MicroRNAs are small, noncoding RNA molecules of about 20-22 bases in 
length, that bind to the 3'-untranslated region of target mRNA, affecting 
important cellular processes, like cell proliferation and differentiation, cell 
cycle, and other hallmarks of cancer, such as inhibition of apoptosis, 
epithelial-to-mesenchymal transition (EMT), cell invasion and metastases, 
more recently addressed as responsible for chemoresistance in several 
common therapies (110). Although the mechanism of microRNA-
mediated drug resistance is not fully understood, an increasing number of 
evidence suggests their involvement in the acquisition of tumor cell drug 
resistance, pointing towards the need for novel and more innovative 
therapeutic approaches. Indeed, this aspect is particularly relevant, since 
therapeutic failure still accounts for death in over 90% of patients with 
metastatic cancers, indicating that a deeper understanding of the 
mechanisms underlying resistance to therapy is urgently needed, in order to 
increase chances of survival and improve quality of life in poor prognosis 
metastatic patients. 
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Aim of the Study 
 
Cancer is a multifactorial disease, deriving from a combination of genetic, 
environmental and lifestyle factors. Particularly, plenty of data reported that 
tumor cells exhibit profound genetic, biochemical and histological difference 
when compared to non-transformed cells of origin, and large attention is 
nowadays dedicated to the metabolic reprogramming of cancer cells, 
resulting in a predominantly glycolytic phenotype (the so-called Warburg 
effect). 
Considering the pivotal role of mitochondria, that supply nearly the total 
amount of energy to the cells and are fundamental key mediators in cellular 
life and death processes, in the last decades it has become increasingly clear 
their involvement in many diseases, including cancer (10). Moreover, the 
effect of several conventional therapeutic drugs on cancer metabolism 
pushed research over the last years to develop new strategies to identify new 
potential therapeutic targets, like key metabolic enzymes with a central role 
in the energy metabolic pathway.  
In this view, it has been recently reported, by Cuezva and co-workers, that 
the endogenous inhibitor protein of the ATP synthase (IF1) is over-expressed 
in different human cancers, when compared to non-transformed cells of the 
same origin. This small and evolutionary highly conserved protein is the 
master regulator of the ATP hydrolytic activity of the ATP synthase, activated 
in response to the acidification of the mitochondrial matrix - which usually 
accompanies the inhibition of mitochondrial respiration (i.e. during 
hypoxia/ischaemia) - and in response to the reversal of F1Fo-ATP synthase 
activity. Furthermore, this protein has been recently investigated for its role 
in inducing the dimerization of ATP synthase, thereby promoting the 
formation of mitochondrial cristae and influencing shape and size of 
mitochondria. Additionally, a protective effect against ROS production and 
apoptosis has been proposed, therefore suggesting that the enhanced 
 Simona Barbato Pag. 45 
 
expression of the protein may represent an advantage in cancer cells, 
promoting cell survival and proliferation, despite the hostile conditions 
experienced by cancer cells. Indeed, a limitation in oxygen and substrates 
availability often occurs within tumor, deriving from an inefficient 
development of vasculature inside the tumor mass: in these conditions, IF1 
may help tumor cells to preserve ATP, critically required for cancer 
expansion, and even act as a molecular switch in favor of glycolysis.  
However, data reported in literature are highly controversial and hypothesis 
on the contribution of the inhibitor to modulate cancer metabolism, as well 
as malignant progression, are not clear. Some recent investigations have set 
out to explore the functional consequences of varying IF1 expression levels in 
cancer cell lines: nonetheless, most of these studies were performed through 
transient modulation of IF1 expression, a model which is characterized by an 
heterogeneous population of cells, in a dynamic condition in which cells are 
adapting to the change in IF1 content. Therefore, to shed light over the 
contribution of the inhibitor and possibly clarify some ambiguities reported, 
the main purpose of this study was to investigate the cellular response to a 
fully and permanent silencing of the protein in a highly IF1 expressing 
osteosarcoma cell line (143B cells).  
In addition, recent literature has also clearly evidenced that epigenetic 
alterations play a crucial role in modifying genes expression, as well as in 
modulating cancer cell metabolism, sustaining and promoting tumor growth 
and dissemination. Indeed, numerous studies have provided convincing 
evidence on the close correlation between microRNAs and tumors (111), 
revealing that these molecules affect cell fate determination, apoptosis, 
migration and invasion, as well as the response of tumor cells to anticancer 
therapies (110). In addition, miRNA expression is also characteristic for 
different cancer types, stage, and other clinical variables, further than 
distinguish tumors from normal tissues. 
In an attempt to explore miRNAs contribution in modulating bioenergetics of 
different tumor cell lines, the pattern of miRNAs expression was analyzed, 
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aiming to explore how these molecules alter metabolic pathways that may 
lead to cancer. However, compelling emerging data on different cell lines, 
including sensitive- and resistant-to-treatment melanoma cell lines, revealed 
a specific pattern of miRNAs expression, along with the acquired resistance 
to BRAF-I treatment, the major breakthrough in the treatment of  
BRAF(V600E) mutation-carrying melanomas. These data seemed quite 
intriguing, prompting us to further investigated over molecular mechanisms 
by which certain miRNAs trigger resistance to therapy in these severe, 
challenging and yet poor-prognosis malignancies. 
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Materials & Methods 
 
1- Cell Culture 
Human osteosarcoma 143B cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% bovine serum, 100 U/ml 
penicillin, and 100 μg/ml streptomycin 0.25 µg/ml amphotericin B, in 
presence of 25 mM glucose, 4 mM glutamine and 1 mM pyruvate. To ensure 
selection, IF1 silenced clones were cultured in presence of 1 µg/ml 
Puromycin.  
Cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO2. 
During experimental procedures, cells were seeded in complete medium (i.e. 
described above) the day before the experiments, to favour adhesion. After 
12 hours, the medium was replaced with fresh media and cells were cultured 
at 37 °C. 
The substrates glucose and pyruvate were purchased from Sigma; all the 
other cell culture reagents were from Gibco (Life Techologies). 
The parental BRAF(V600E) melanoma M21, Colo38 and SK-Mel37 cells were 
originated from metastatic lesions of patients with melanoma. Cells were 
cultured in RPMI-1640 (Life Technologies) supplemented with 10% FBS 
(Omega Scientific), 100 units/ml of penicillin, and 100 μg/ml of streptomycin 
(Life Techologies) in a humidified HERA-cell 150i incubator at 37̊ ºC in an 
atmosphere of 5% CO2. 
Derivative melanoma cells with acquired vemurafenib resistance (M21-R, 
Colo38-R and SK-Mel37-R), were generated by propagating M21 and Colo38 
parental cells in increasing concentrations of BRAF-I (Vemurafenib) up to 2 
and 5 µM, respectively. After two months, resistant cells were isolated from 
each of the two cell lines and cultured in presence of 0.5 and 5 µM PLX4032 
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Both parental and derivative BRAF-I resistant melanoma cells were kindly 
provided by Dr. Soldano Ferrone (PhD, MD), from Harvard University. 
 
2- Bacterial Transformation & plasmid isolation 
After obtaining competent DH5α - E. Coli cells, standard protocol was 
followed for transformation. Briefly, the ligation products were added to the 
bacteria, kept in ice for 10 minutes, heated at 42 °C for 45 seconds and cooled 
2 minutes in ice. Then, bacteria were grown for 1 hour in 1 ml of SOC 
medium, composed of 20 gr/L LB broth, 1M MgCl2, 1M MgSO4, 2M Glucose 
(Sigma-Aldrich).  
Bacterial colonies transformed with pGFP-V-RS or pCMV6-XL4 plasmid were 
selected in 35 gr/L LB agar plates containing 100 μg/ml Ampicillin (Sigma-
Aldrich). 
Each colony was collected, expanded at 37 °C overnight in 20 gr/L LB broth 
with 100 μg/ml Ampicillin and finally, the plasmid DNA was purified from 
bacteria using Pure Yeld plasmid Maxiprep kit (Promega), according to 
manufacturers’ instructions. The concentration was then assessed through a 
NanoDrop spectrophotometer (Thermo-Scientific) 
 
3- Cell Transfection 
3.1- RNAi silencing through shRNA  
Human osteosarcoma 143B cells were transfected with a shRNA sequence to 
permanently silence the ATPIF1 gene. For transient co-transfection we used 
pCMV6-XL5-IF1 expression plasmid, together with alternatively a single 
shRNA vector or a scrambled negative control constructs cloned in pGFP-V-
RS plasmid (#1 GI325933, #2 GI325934, #3 GI325935, #4 GI325936 and 
TR30013, respectively). All the plasmids used were from Origene (Rockville, 
MD, USA).  
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Briefly, cells were seeded the day before transfection in 35 mm Petri dishes, 
in order to have 60-80% of confluence for the transfection procedures. The 
following day, equal amount of the two vectors (4 µg total DNA) were 
transfected overnight using polyethylenimmine linear, MW ~25,000 
(Polysciences, Inc.) (PEI), according to manufacturers’ instructions, with a 
1:7 DNA:PEI ratio. After 24h, the medium was replaced with complete DMEM 
and cells were cultured for further 24 hours before the analysis of IF1 
silencing level. 
The 29 pb gene silencing shRNA sequence (5’- 
AAACACCATGAAGAAGAAATCGTTCATCA-3’), contained in the plasmid #4 
GI325936, granted the best efficiency of transfection. Therefore, parental 
143B cells were seeded and transfected - as described above - with 2 µg of 
either GI325936 or TR30013 plasmid DNA. 48 hours later, cells were split 
and selected for stable transformation in the presence of 1 µg/ml puromycin, 
changing the medium every day.  
Single colonies were then subcloned by limiting dilution and finally all the 
clones obtained were assayed for the IF1 expression level. Clones with the 
lowest expression of IF1 where then expanded to perform all the 
experimental assays. 
3.2-  miRNAs 
The expression levels of miRNAs (i.e. miR-136) were altered by transient 
transfection with miR-136 mimic or inhibitor. After being cultured in fresh 
medium over-night, adherent melanoma cells were alternatively transfected 
with 50 nM of hsa-mir-136-5p mimic or inhibitor (Life Technologies), using 
scrambled sequences as a negative control. Cells were transfected using 
RNAiMAX Lipofectamine reagent (Life Technologies) in SFM Opti-MEM (Life 
Technologies), according to manufacturer’s instructions. MiR-136 levels were 
then assayed by q-RT-PCR to verify the successful transfection. 
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4- Cell Growth Evaluation 
Cell growth of parental and IF1-silenced 143B cells was assessed after 
seeding 2×105 cells - in triplicate - in complete DMEM in 35 mm Petri dishes 
and culturing for up to 72h.  
Adherent cells were trypsinized and collected, and the growth ability of cell 
lines was assayed using trypan blue exclusion test, counting cells every 24 h, 
without changing the medium.  
Melanoma cell growth was assessed in three independent experiments after 
seeding 1,5 X 105 cells in 6-wells plates in complete medium (three 
independent wells per each time point). After being cultured in fresh medium 
over-night, parent M21 and Colo38 cells were transfected either with 
scrambled or miR-136 and grown further 24h before treating with 0.5-5 µM 
PLX4032 (respectively), in order to maximize miR-136 effect. Cells were 
counted every 24h up to 120h from the beginning of vemurafenib treatment. 
By contrast, resistant M21-R and Colo38-R were transfected in their normal 
condition (i.e.: under PLX4032 treatment) and counted up to 120h since 
transfection, either with scrambled or miR-136-inhibitor (Life Techologies).  
Cells were harvested together with supernatant and counted every 24h 
without changing the medium, to assess the total number of cells, using a Vi-
CELL XR 2.03 (Beckman Coulter, Inc.). 
 5- Cell viability and Annexin V assays 
Cell viability was assessed on fluorescent-based analysis through MuseTM 
Count & Viability Kit (Millipore). In the assay, both viable and non-viable cells 
are stained and distinguished on the basis of their permeability to the DNA-
binding dyes in the reagent. 
Essentially, cells were harvested and washed in PBS solution. After 
centrifugation, pellets were resuspended in PBS and incubated with MuseTM 
Count & Viability reagent for 5 minutes at room temperature, protected from 
 Simona Barbato Pag. 51 
 
light. At least 10,000 events were acquired with MuseTM Cell Analyzer and 
data were expressed as Total and Viable cells/ml. 
Detection of apoptotic cells was carried out exploiting the translocation of 
phosphatidylserine (PS) residues from the cytoplasmic face of the plasma 
membrane to cell surface. Annexin V-PE is used to detect PS on the external 
membrane of apoptotic cells.  
After culturing cells, including for positive and negative controls, 143B cells 
were collected and resuspended in the Assay Buffer HSC (Millipore) and 
incubated at room temperature for twenty minutes, with the Muse™ Annexin 
V & Dead Cell reagent (Millipore), containing a mixture of a cell impermeant 
dye, as an indicator of membrane structural integrity, and a fluorescent 
conjugate for the detection apoptosis. 
Cells were then analyzed by MuseTM Cell Analyzer, after 10,000 acquisitions 
and the concentration (expressed as Cells/ml) and percentage of the four 
distinct populations were determined: live, early and late apoptotic, dead 
cells. 
 
5- Flow Cytometric Assessment 
Flow cytometry of GFP positive cells was performed using a FACSaria 
cytometer (BD Biosciences). Excitation was at 488 nm and fluorescence 
emission was measured at 580/630 nm.  
Data acquisition and analysis was performed with BD FACS Diva and Flowing 
Software, respectively. 
 
6- Mitochondrial membrane potential  
The inner mitochondrial membrane potential was measured by staining cells 
with 20 nM tetramethylrhodamine methyl ester (TMRM) (Molecular Probes, 
Eugene, OR), a lipophilic probe that enters mitochondria in a ΔΨm-dependent 
manner (112). 
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After culturing, cells were incubated with the probe for 30 min at 37 °C in the 
absence or presence of 0.6 µM oligomycin and wells were then washed twice 
with Hanks’ balanced salt solution to remove any remaining unincorporated 
dye. The cells were rapidly trypsinized, diluted to the optimal density 
(300,000 cells/ml) with Hanks’ balanced salt solution supplemented with 
10% FBS and immediately analyzed with the MUSE cell analyzer (Millipore, 
Billerica, MA).  
Excitation was at 532 nm and fluorescence emission was measured at 
576/28 nm. Data acquisition and analysis were performed with MuseSoft 
Analysis and Flowing software, respectively. A total of 10,000 events were 
acquired for each determination. 
 
7- Brightfield and Fluorescence Microscopy 
Brightfield and fluorescence images of controls and IF1-silenced cells were 
acquired using a fluorescence inverted microscope (Olympus IX50 equipped 
with a CCD camera).  
Multiple high-power (magnification X10 and X40) images were acquired with 
IAS2000 software (Delta Sistemi, Roma, Italy). Fluorescence photographs of 
GFP-positive cells were obtained using a specific set of filters: excitation 
480/30 and emission 530/30.  
Mitochondrial network morphology and membrane potential were evaluated 
by incubating cells with 20 nM TMRM for 30 min. At least 10 different optic 
fields were acquired for every experimental condition tested. 
 
8- Protein concentration 
The protein concentration was determined using the Lowry method (113). 
Basically, the sample was treated with 5% Na-deoxycholate and 
subsequently incubated for 10 minutes in the presence of a reaction mixture 
constituted by 2 % Na2CO3 and 0.1 M NaOH (Reagent 1), 2 % Na-K tartrate 
 Simona Barbato Pag. 53 
 
(Reagent 2) and 1% CuSO4 (Reagent 3) in a stoichiometric ratio of 100:1:1. 
The mixture was then added with the Folin-Ciocalteu to a final concentration 
of 3%. After 30 minutes of incubation at RT, the concentration of the reduced 
Folin reagent was measured at 750 nm in a V-450 Jasco spectrophotometer.  
The total concentration of protein in the sample was determined on the basis 
of a standard curve, using bovine serum albumin (BSA, Sigma) as a standard.  
 
9- Mitochondria Isolation 
Coupled mitochondria were isolated from cells according to the method by 
Kun et al. (114), modified to exclude digitonin treatment, as described 
previously (115). 
Essentially, cell homogenates were obtained using a glass Potter-Helvehjem 
homogenizer with a motor-driven Teflon pestle in isolation buffer (0.22 M 
mannitol, 0.07 M sucrose, 0.02 M HEPES, 1 mM K- EDTA, 0.1 mM K-EGTA, pH 
7.4) containing 1 mM PMSF (phenylmethanesulfonyl fluoride). Crude extracts 
were centrifuged at 2000 g for 10 min (Sorvall SS34 rotor) to remove nuclei 
and plasma membrane fragments, and then the supernatant was centrifuged 
at 10,000 g for 10 min (Sorvall SS34 rotor) to obtain the mitochondrial pellet. 
Mitochondria were washed in 0.25 M sucrose, 0.02 M HEPES, 1 mM K-EDTA, 
and 0.1mM K-EGTA, pH 7.4, and resuspended in the same buffer to a 
concentration of 10 mg/ml of protein. 
 
10- BN-PAGE and Western Blot Analysis 
The organization of the ATP synthase complex and the binding of IF1 to the 
monomeric and/or oligomeric form of the enzyme were analyzed in 
digitonin-treated mitochondria (2.5:1 (w/w) digitonin : protein ratio) by 
one-dimensional blue native-PAGE (116). 
Following electrophoresis under non-denaturating conditions, proteins were 
immediately electroblotted onto nitrocellulose membranes under denaturing 
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conditions. ATP synthase and IF1 protein bands were detected using anti-α 
subunit and anti-IF1 primary monoclonal antibodies (MitoSciences Inc.), 
respectively, and a secondary goat anti-mouse IgGH+L antibody labeled with 
horseradish peroxidase (Invitrogen).  
The immunoblots were detected and quantified by chemiluminescence using 
the ECL Western Blotting Detection Reagent Kit (Amersham Biosciences). 
 
11- In-gel ATPase Activity 
Immediately after the electrophoretic run of the protein complexes extracted 
from digitonin-treated mitochondria, ATPase activity was assayed on the 
native gel using an enzymatic colorimetric method (117). Whitestained ATP 
synthase bands were acquired using a GS-800 densitometer (Bio-Rad) with a 
blue filter to minimize the interference from the residual Comassie Blue. 
 
12- SDS-PAGE and Western Blot Analysis 
Cellular lysates were separated by SDS-PAGE and blotted onto nitrocellulose 
membranes to perform semi-quantitative analysis of protein content, 
according to Baracca et al. (118).  
Cells were lysed with ice-cold RIPA buffer (pH 8.0, containing 50 mM Tris-
HCl; 150 mM NaCl; 0.1% Triton, 0.1% Na-DOC, 0.1% SDS), supplemented 
with 5 µL/ml of a mixture of protease inhibitors and 1 mM PMSF (Sigma).  
Equal amount of protein diluted in Sample Loading Buffer (3.56 mM SDS, 
36% glycerol absolute; 0.5 M Tris pH 6.8; Bromophenol Blue 10, 4 µM; β-
Mercaptoethanol 5%), were denaturated for 5 min at 100ºC and loaded into a 
sodium dodecyl sulfate–polyacrylamide gradient gel  (12-20%). 
Following SDS-PAGE electrophoresis, proteins were immediately 
electroblotted onto a nitrocellulose membrane (BioRad). Membranes were 
then saturated with a solution of fat-free milk powder (BioRad) in PBS and 
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0.1% Tween-20 (BioRad) for 1 hour at room temperature and incubated with 
primary antibodies, specific for the d-subunit of F1F0-ATPase (19 kDa) and 
for IF1 (12 kDa), or with a mixture of five primary mouse monoclonal 
antibodies specific for single subunits of each OXPHOS complex 
(MitoSciences Inc., Eugene, OR) as reported in Sgarbi et al. (119). Antioxidant 
enzymes were detected by rabbit polyclonal primary antibodies specific for 
Catalase (60kDa) and Cu-Zn SOD (17 kDa), and mouse monoclonal primary 
antibodies targeting Mn-SOD (25 kDa), GPX-1 (22 kDa), all purchased by 
Abcam (MitoSciences Inc., Eigene, OR) 
Samples deriving from melanoma patients were incubated with a rabbit 
monoclonal antibody specific for SUFU (55 kDa) and PDGFRα (90 kDa) 
primary antibody (Cell Signaling).  
Actin (42 kDa) and porin (35 kDa), used as loading controls for cells and 
mitochondria, respectively, were  immunodetected with mouse monoclonal 
anti-actin (Sigma) and anti-porin (Mito-Sciences Inc., Eugene, OR) primary 
antibodies.  
Immunodetection of primary antibody was carried out with secondary goat 
anti-mouse or anti-rabbit IgGH+L antibody (Invitrogen) labeled with 
horseradish peroxidase.  
Chemiluminescent detection of the specific proteins was performed with the 
ECL Western blotting Detection Reagent Kit (GE Healthcare, Waukesha, WI) 
using the ChemiDoc MP system equipped with the ImageLab software (Bio-
Rad) to perform the densitometric scanning of the relative protein intensity. 
 
13- Citrate Synthase Activity 
The activity of the enzyme citrate synthase, taken as an index of 
mitochondrial mass, was assayed as described by Trounce et al., 1996, (120), 
by following spectrophotometrically the reduction of  5,5' - dithiobis 2 - 
nitrobenzoic acid (DTNB) in a reaction coupled with acetyl - CoA and 
oxaloacetate. Essentially, the reaction catalyzed by citrate synthase produces 
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CoA–SH, which react with the DTNB by breaking the disulfide bridge, and 
producing the ion 2-nitro -5-tiobenzoato (NTB) in a  stoichiometric ratio.  
The assays were conducted at 30 °C by incubating 20–30 μg protein in Tris-
HCl buffer 125 mM (pH 8), 0.2% triton, 0.1 mM acetyl-coenzyme A, 0.1 mM 
5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), and 0.5 mM oxaloacetate. The 
activity was assessed by monitoring the release of 2-nitro-5-thiobenzoate at 
412 nm (ε=13.6 mM−1 cm−1), as previously described (121) (122). After the 
determination of protein concentration, by the Lowry method, the activity 
was expressed as nmol/min/mg protein. 
 
14- Intracellular steady-state ATP 
The intracellular steady state of ATP was determined by the luciferin - 
luciferase bioluminescent method (ATP bioluminescent assay kit CLS II; 
Roche; Basel, Switzerland), using an internal standard with a known amount 
of ATP (33 pmol), as described before (123). 
Cells were seeded (4x105) in complete medium and the following day fresh 
media were replaced to all samples. Then, cells were washed in PBS, rapidly 
resuspended in a buffer containing 10mM Tris-Hcl, 100mM KCl, 5 mM 
KH2PO4, 1 mM EGTA, 3 mM EDTA, 2 mM MgCl2 (pH 7.4) and then lysed in 
DMSO to release the ATP content at the intracellular level.  
After determining the protein concentration of the intracellular content, ATP 
levels were expressed as nmol/mg protein. 
 
15- ATP synthesis Rate 
The rate of mitochondrial ATP synthesis was measured using the method 
reported by Sgarbi et al., 2006. (124). 
Essentially, cells were washed in PBS and then resuspended in a buffer 
containing 10 mM Tris, 100 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 3 mM EDTA, 
2 mM MgCl2 (pH 7.4). Cells were then incubated in the presence of digitonin 
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60 μg/ml (to permeabilize the plasma membrane), 2 mM iodoacetamide (to 
inhibit ATP synthesis from cytoplasmic glycolysis) and 1.25 mM adenosine 
pentaphosphate (myokinase inhibitor). Complex I driven ATP synthesis was 
induced by adding 10 mM glutamate/malate and 0.5 mM ADP to the sample. 
After 3 minutes, the reaction was stopped by adding dimethylsulfoxide 
(DMSO).  
The amount of ATP product was then determined by means of the luciferin-
luciferase bioluminescent method (ATP bioluminescent assay kit CLS II; 
Roche, Basel, Switzerland), using as a reference an internal standard with a 
known amount of ATP (33 pmol).  
The ATP measured was referred to the protein content, determined by the 
method of Lowry, and the ATP synthesis rate was expressed as 
nmol/min/mg protein. 
 
16- ATP hydrolysis 
The ATPase activity was determined spectrophotometrically measuring the 
oxidation of NADH at 340 nm obtained coupling two reactions catalyzed by 
pyruvate kinase (PK) and lactate dehydrogenase (LDH) respectively in 
presence of phosphoenolpyruvate (PEP) in a V-450 Jasco spectrophotometer 
(125). 
After isolating mitochondria as described before, samples were divided into 
two different aliquots to be assayed at two different pH (i.e. pH 7.4 and 6.7).  
The assays were performed at 30 °C with an ATP regenerating system in 25 
mM TRIS/acetate, 25 mM KCl, 5 mM MgCl2. 30 μg of mitochondria were 
incubated with 4mM ATP, 160 μM NADH, 5 μM Rotenon, 1,5 mM PEP and 
LDH/PK. F1Fo ATPase activity was calculated as the difference between total 
and oligomicin-sensitive ATPase activity and finally was expressed as 
nmol/min/mg. 
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17- Glucose consumption and Lactate release    
assay 
Glucose consumption and lactate production were determined by a 
colorimetric-enzymatic procedure, firstly described by Trinder in 1969 
(126), that exploits the production of hydrogen peroxide (H2O2), peroxidized 
to form a colored compound, directly proportional to the amount of 
Glucose/Lactate in the sample.  
The colorimetric determinations were conducted on the culture medium 
after the treatment of cells. Briefly, 4x105 cells were seeded in complete 
medium. After 24 up to 72 hours of cell culturing, the supernatants were 
extracted and dosed by Glucose liquid and Lactate PAP fluid kit (FAR 
diagnostic; Verona, Italy and Centronic GmbH; Wartenberg, Germany, 
respectively) at 37 °C, following manufacturers’ instructions.  
Using an internal standard of known concentration (5.55 mM Glucose 
standard, 30 mg/dl lactate standard), absorbance was measured 
spectrophotometrically (510 nm and 546 nm, respectively) to trace the 
amount of Glucose residue or Lactate produced. Data were then reported to 
the number of moles and normalized by the number of cells and expressed as 
µmol/106 cells. 
18- Analysis of Intracellular ROS in Live Cells 
(CellRox® Orange & CellRox® Deep Red) 
Reactive oxygen species (ROS) in live cells were detected and quantified 
alternatively by the cell-permeant fluorogenic reagent — CellROX® Orange 
or CellROX® Deep-Red (both from Thermo Fisher Scientific). The reagents 
are non-fluorescent in the reduced state, but exhibit strong fluorescence 
upon oxidation and remain localized within the cell. 
Briefly, cells were grown up to 72 hours, washed once with PBS and loaded 
with 5 μM CellROX® Orange or Deep Red probe (Thermo Fisher Scientific) in 
complete medium without FBS for 30 minutes in the dark. After loading, the 
dye was removed by washing the cells twice with PBS.  
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Cells were then tripsynized and intracellular ROS content was detected 
acquiring at least 10,000 events with the FACSaria flow cytometer (Deep Red 
probe) or with MuseTM Cell Analyzer (Orange probe), by measuring the 
fluorescence emission at 576/680 nm (excitation at 405 nm and 532 nm, 
respectively). 
19- Oxygen Consumption Rate 
Parental and IF1 silenced clones were assayed for the oxygen consumption 
rate both in intact and permeabilized cells, using an oxygen Clark-type 
electrode as previously reported by Baracca et al. (118).  
Measurements were conducted at 30 °C, with a 7.4 pH buffer containing 
0.25M Sucrose, 20 mM Tris, 4 mM MgSO4, 0.5 mM EDTA, 10 mM KH2PO4. In 
these conditions, the solubility of oxygen is equal to 204.1 mM. 
Intact cells were harvested and resuspended in the aforementioned buffer 
and directly analyzed in the Stratkelvin’s chamber for about 5 minutes, to 
assess endogenous respiration.  
Alternatively, cells were permeabilized with digitonin (60 μg/ml) to favor the 
entry of 10 mM glutamate, 10 mM malate (plus 1.8 mM malonate) as 
substrate of NADH(H+) - dehydrogenase Complex I, or 20 mM succinate (plus 
4 µM rotenone) as substrate of succinate – dehydrogenase. 
State 3 and uncoupled respiration rates were measured in the presence of 0.5 
mM ADP or 60 µM dinitrophenol, respectively. State 4 was established by 
adding 1.5 µM Oligomycin. 
The oxygen consumption rate was referred to protein concentration, 
determined by the Lowry method, and expressed as nmol O2/min/mg 
protein.  
20- Dual Luciferase Assay  
A luciferase reporter construct was generated by cloning eight repeated 
copies of wild-type or mutated Gli-binding sites (3’GliBS or mut3’Gli-BS, 
respectively) into a psiCHECK™-2 Vector (Promega), to control the 
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expression of a Firefly Luciferase (Photinus pyralis) to assess the Shh 
Pathway activation. The plasmid was kindly provided by Dr. Hiroshi Sasaki 
(Laboratory for Embryonic Induction, Japan) and was co-transfected together 
with Renilla luciferase (Renilla reniformis, also known as sea pansy) 
containing pRLTK vector, as internal control.  
Briefly, Melanoma parent cells M21 and Colo38, as well as BRAF-I resistant 
derivative M21-R and Colo38-R, were seeded into 12-well plates for 24h (5 X 
104 per well). Then the cells were co-transfected with 1 µg DNA of each 
reporter vector, and with 50 nM miR-136 mimic or scrambled control. After 
24 and 48 hours from transfection, cells were lysed, and ratios between 
Firefly and Renilla luciferase activity were estimated using the Dual 
Luciferase Assay Kit (Promega) according to the manufacturer’s instructions.  
Data were repeated at least three times, using a GloMax® 96 Microplate 
Luminometer (Promega) and presented as the mean value of Firefly/Renilla 
luciferase ratio. 
21- miRNAs-gene targeting prediction 
MicroRNAs databases were used to acquire information on miRNA sequence 
data and their genomic targets, mostly based on miRanda algorithm (v3.0) to 
detect potential microRNA target sites in genomic sequences (127). 
The main software used were: microRNAs.org, miRbase, miRDB, miRwak2.0 
(128). The provision of a p-value for each miRNA–target assignment allows 
the user to assess the confidence in the prediction. 
22- Real-time quantitative RT-PCR  
Semiquantitative reverse transcription–polymerase chain reaction (RT-PCR) 
was performed to assess miR-136 levels in wild type and miR-136 (either 
mimic or inhibitor) transfected melanoma cells.  
Total RNA was isolated using TRIzol reagent (Life Techologies), according to 
the manufacturer’s instructions.  
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The total RNA from each sample was reverse-transcribed into cDNA with the 
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems), 
according to manufacturer’s instructions.  
Expression analysis of miRNAs was performed with TaqMan primers and 
probes (Life Technologies) for miR-136 and the small nuclear U6 RNA, used 
as miRNA internal control.  
Real time PCR was performed using a CFX96 real-time PCR system (BioRad). 
MiRNA relative expression levels were normalized to U6 by the 2-ΔΔCt method 
and data were presented as miR-136/U6 fold change. All reaction were 
performed in triplicate and repeated twice. 
23- Data Analysis 
Results are average ± SD of 4-6 samples from at least two independent 
experiments. Statistical analyses were performed using the OriginPro 7.5 
software (Origin-Lab Corporation, Northampton, MA, USA) applying the 
analysis of variance (ANOVA) test followed by the Bonferroni means 
comparison. Statistical significance was defined by p ≤ 0.05. 
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Results - 1st part: IF1 
1- IF1 expression and shRNA-mediated stable 
silencing 
 
The mammalian mitochondrial ATP synthase is finely regulated by the 
endogenous inhibitor IF1, a protein which binds at the α/β catalytic sites and 
inhibits ATP hydrolysis. The binding of IF1 to the enzyme is ΔΨm and pH 
dependent, being the latter optimal under neutrality: when the aerobic 
proton motive force declines, like in ischemia or respiratory impairment, the 
protein becomes active to prevent a massive and useless dissipation of 
energy inside the cell. Conversely, in conditions of normal electrochemical 
proton gradient, IF1 does not inhibit the enzyme, which normally synthesizes 
ATP (48). 
Most investigations into the pathophysiological role of IF1 and the F1F0-
ATPase have been done in the context of myocardial ischemia (19). To note, 
similar conditions might be found in tumor cells, where oxygen levels vary 
from the perivascular regions to the anoxic necrotic centers (129). In these 
conditions, IF1 could play an important role in the pathology of tissue 
ischemia and tumor growth, by helping cells to conserve ATP. Confirmations 
of this hypothesis can be found in the overexpression of the protein 
registered in many human carcinomas (65), that prompted researchers to 
focus on the contribution of the inhibitor in modifying cancer metabolism.  
In this context, IF1 may therefore represent an efficient strategy of cancer 
cells to overcome hostile conditions; nevertheless the importance of this 
protein has not been definitively established and conflicting data have been 
reported, encouraging us to investigate over the bioenergetics of tumor cells 
following the variation of IF1 levels. 
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1.1- Cell model: Human osteosarcoma 143B cells 
As a starting point, a number of different cell lines was screened and 
immunodetected for IF1, to assess the expression levels of the protein in 
different cell types. Among these, we found that the human osteosarcoma 
143B cell line expresses high levels of the inhibitor (Figure 17, A and B), so 
we decided to explore the cellular response to the silencing of IF1, aiming to 
shed light on the contribution of the inhibitor to the typical metabolic 
changes of the transformed cells. 
 
 
 
Figure 17: IF1 level in different immortalized and tumor cell lines.  
(A) Representative immunoblot analysis of IF1 protein level in different cell lines. Actin 
and porin were both used as loading control and mitochondrial content respectively. 
(B) Graph shows the densitometric analysis of IF1 level normalized over the porin and 
bars represent the mean ± SD of two independent experiments. Cell lines used were as 
follow: PC12 = Rat adrenal phaeochromocytoma cell line; MEF = mouse embryonic 
fibroblasts; 143B = human osteosarcoma cell line; RD = human rhabdomyosarcoma 
cell line; SH-SY5Y = human neuroblastoma (N-type) cell line; SH-EP = human 
neuroblastoma (S-type) cell line; T67 = human astrocytoma cell line; LAN-1 = human 
neuroblastoma (N-type) cell line. 
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1.2- Assessment of the most efficient shRNA sequence 
Some recent investigations in the pathology of tissue ischemia and tumor 
growth have been set out to explore the functional consequences of varying 
IF1 expression levels in tumor cell lines, by transient transfection or 
temporary knocked-down of the protein. Nevertheless, studies on transiently 
transfected cells do not represent a stable steady-state metabolic condition, 
but a dynamic situation in which cells are adapting to the variation of IF1 
content, producing potentially ambiguous results, like the controversial data 
reported in the literature. Therefore, in the first part of our study we focused 
on fully silencing of the inhibitor through an RNA-interference technique, 
mediated by shRNA sequences directed to the ATPIF1 gene.  
For this reason, four IF1 gene-specific shRNA expression plasmids (Figure 18, 
A) were tested to identify the 29mer shRNA sequence with the highest IF1 
silencing competence (Figure 18, B). 
 
A 
 B 
 
Figure 18: Silencing of the IF1 inhibitor protein: assessment of the most efficient 
shRNA sequence.  
(A) Nucleotide sequence of the four shRNA constructs, specific for human IF1 mRNA 
(spanning the 3' end of the IF1 mRNA) cloned in the pGFP-V-RS vector. (B) Map of the 
plasmid #4 showing the complete sequence of the construct (target sequence, loop and 
reverse complementary sequence), cloned under the control of the U6 promoter, and the 
termination sequence TTTTTT located immediately downstream of the shRNA construct. 
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The transient co-transfection of the cells with the IF1 expression plasmid 
together with the four shRNA constructs, resulted in different efficiency of 
silencing, with a maximal reduction (about -70%)  observed using plasmid 
#4 (Figure 19). 
 
Figure 19: Immunoblot analysis of IF1 protein levels after transient co-
transfection with both the IF1 overexpression plasmid and alternatively one of 
the four shRNA or the scrambled plasmids (#1-4 plasmids as specified in Materials 
and Methods). 
 
 
1.3- IF1 silencing: stable clones IF1-KD were established 
Once identified the sequence that granted the best silencing, cells were 
alternatively transfected with #4 or a scrambled plasmid, containing a 
random nucleotide sequence, (same length of GI325936 sequence, but not 
coding for any human mRNAs), in order to obtain a stable suppression of the 
inhibitor and its proper control. After 24 hours of culture, an overall 30% of 
population was positively transfected (Figure 20, lower panel), as estimated 
on the basis of the GFP fluorescence - GFP being encoded by each shRNA 
plasmid – and cells were displaying a similar morphology, independently 
from the presence - or absence - of the inhibitor (Figure 20, upper panel).  
Positive transfected cells were then selected in Puromycin and subcloned by 
limiting dilution, to obtain several clones (starting from individual GFP-
expressive-cells) from both scrambled and shRNA #4 plasmids. Clones were 
then assayed by SDS-PAGE to evaluate the IF1 expression levels after 
silencing: as shown in Figure 21, the immunodetection of IF1 exhibited a 
remarkable reduction of expression in all the silenced clones. To note, 
densitometric analysis of the bands revealed that clones A7 and D9 
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expressed the least IF1 content, as they resulted in 6 and 9% of the controls, 
respectively.  
 
Figure 20: Bright-field and fluorescence microscopy images of 143B cells 
transiently transfected with either the scrambled or the sh-IF1 #4 plasmids.  
The pictures are representative of several observations (magnification X10). 
 
 
 
Figure 21: Immunoblot analysis of the IF1 protein level in parental (143B cells), 
scrambled clones (B3 and D1), and IF1-depleted clones (A7, B7, B8, C7, C9, D7, 
D9, D10). 
 
Transfection stability and cell homogeneity of IF1 silenced and scrambled 
clones were evaluated by both fluorescence microscopy (Figure 22, A) and 
flow cytometry (Figure 22, B), confirming that almost the totality of cells 
were positive for GFP expression (around 99% on total). 
At the same time, neither transfection procedures, nor the absence of the 
protein affected cell morphology, since both silenced and scrambled clones 
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maintained the same morphology of the untransfected cells (Figure 22, A). 
Indeed, the bright-field microscopy images revealed that the adhesion 
capacity of the clones was unaltered with respect to the parent cells (Figure 
22, A). 
 
A 
B 
 
Figure 22: Transfection stability and cell homogeneity of IF1 silenced and 
scrambled clones.  
(A) Bright-field and fluorescence (GFP) microscopy images of 143B cells, scrambled 
clone B3 and IF1-silenced clones A7 and D9 (magnification X10). The pictures are 
representative of several optical fields. (B) Typical flow cytometry GFP-positive cells 
distribution in controls and IF1-depleted clones. 
 
In addition, to avoid interferences with some probes used in the following 
experiments - and to verify that no artifacts resulted from the expression of 
the GFP - some IF1-silenced clones not expressing GFP were isolated from the 
starting transfected population and run on a SDS-PAGE to verify successful 
silencing of the protein. However, comparable amount of IF1 to the 
aforementioned clones were immunodetected in G3 and E9 GFP- clones, 
confirming an efficiency of silencing of more than 90% (Figure 23). 
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Figure 23: Immunoblot analysis of the IF1 protein level in parental (143B cells), 
scrambled and empty vector clones (sD7, eD7 and eC5 respectively), and IF1-
depleted clones (G3, E9, F8, G8). 
 
2- Biochemical characterization of IF1 - silenced 
clones 
After selecting human osteosarcoma clones with a permanent silencing of the 
endogenous inhibitor of ATP synthase, the main bioenergetics parameters 
were investigated, in order to see if the presence – or absence – of the protein 
was critical for the bioenergetics of the cells. 
 
2.1- Cell viability 
Some studies reported that the overexpression of IF1 is correlated with an 
augmented proliferative response of the cells (130), even in normoxic 
conditions; nonetheless, this has been questioned by others, in a study on 
permanently IF1-silenced HeLa cells, in which IF1 seems not to be essential 
for normal cell growth (131).  
To clarify these conflicting results, the first parameter assayed in our study 
was cell viability, in order to evaluate whether the absence of the protein 
could interfere with the cell proliferation rate. To that aim, cell growth of 
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human osteosarcoma 143B cells was assayed for up to 72 hours, counting 
cells every 24 hours and checking for cell viability.  
 
Figure 24: IF1 does not affect the Viability and Proliferation Rate of 
Osteosarcoma cells. Cells were grown under normal conditions for up to 72h and 
counted every 24h. Parent 143B cells (black), scrambled (blue) and IF1-silenced clones 
(red, A7 and magenta, D9) are shown. Results are represented as the mean of each 
time point ± SD of three independent experiments. 
 
As Figure 24 clearly shows, under normal growth conditions the proliferation 
rate and cell viability of the two silenced clones (red and magenta line) were 
similar to the two control lines (143B, black line; scrambled, blue line). 
Therefore, we assumed that the absence of the inhibitor protein does not 
alter either the speed or the vitality of cancer osteosarcoma cells under 
optimal growth conditions.  
 
2.2- Glucose consumption and Lactate release 
According to some recent studies, IF1 plays a crucial role in mediating the 
metabolic switch experienced by cancer cells – in favor of glycolysis – 
therefore providing an advantageous phenotype to promote cell proliferation 
and invasion (132). Since we showed that the inhibitor was not involved in 
the proliferative response of the cells (Figure 24), nor in modifying cell 
morphology or adhesion capability (Figure 22), we wanted assay whether -  
and eventually to what extent - IF1-null cells consume the substrate glucose 
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and release lactate.  
Nevertheless, the diagrams illustrates that, after 24 hours of cell growth 
under normoxic conditions, the IF1-silenced clones and controls displayed 
the same consumption of the substrate, as well as the same release of lactate 
(Figure 25, A and B, respectively). Incidentally, the lactate release to glucose 
consumption ratio was approximately two, indicating that almost all of the 
glucose consumed by the cells was released into the medium, in the form of 
lactate.  
 
A B 
Figure 25: No difference in Glucose consumption, nor in Lactate release.  
Cells were grown under normal conditions for 24h and media were assayed for 
residual Glucose (A) and Lactate produced (B), as described in Material and Method 
section. Data, expressed as µmol Glucose consumed/Lactate released per 106 cells, 
represent mean value ± SD of three independent experiments. 
 
 
As expected, these data indicate that normoxic conditions do not induce the 
activation of hydrolytic ATP synthase, with the subsequent binding of IF1, 
contrarily to data reported (133). 
 
 
 
2.3- Mitochondrial parameters and ATP content 
Previous studies reported that the knock-down of IF1 caused stimulation of 
autophagy, decrease in mitochondria volume fraction in the cells and the 
decrease in cristae density in mitochondria (60), (63) . 
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However, no changes were reported in our study in absence of IF1: after 
incubating cells with 20 nM TMRM for 30 min, fluorescence microscopies 
revealed an heterogeneous mitochondrial network morphology, with spotted 
and filamentous mitochondria, but silenced clones displayed no prominent 
alteration compared to controls (Figure 26).  
 
 
Figure 26: Mitochondrial network was unaffected by the absence of IF1.  
Parental, scrambled, and IF1-depleted cells were loaded with 20 nM TMRM and 
fluorescence images were obtained using an inverted fluorescence microscope 
(magnification X40). 
 
 
In addition, the mitochondrial content of all the cells types was similar, as 
determined by the citrate synthase assay, taken as an index of mitochondrial 
mass (Figure 27). 
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Figure 27: Mitochondrial mass was not altered by IF1.  
Citrate synthase activity expressed as nmol/min/mg of protein. Bars show the mean ± 
S.D. of five independent experiments. 
  
Consistently, the steady state level of cellular ATP in normoxic conditions 
was unaltered in the absence of the protein, as it was about 25 nmol/mg of 
protein in all cell analyzed, independently from IF1 content, as reported in 
Figure 28. 
 
Figure 28: Steady State levels of ATP.  
The content of ATP was measured by a chemiluminescent method and expressed as the 
number of moles of ATP to mg of protein. The histogram shows the mean value ± 
standard deviation of three experiments independent. 
 
Hereafter, these data suggested that IF1 is not directly involved in the 
remodeling of these organelles, contrary to previous reports (63). On the 
basis of earlier studies on both isolated mitochondria and submitochondrial 
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particles (134) and (135), the above results were expected, since cells were 
grown under conditions that did not favor the binding and inhibition of IF1 to 
the F1F0-ATPase complex. However, Fujikawa et al. (131) reported a nearly 
40% ΔΨm increase in IF1 null cells and proposed that it was the result of an 
increased ATP hydrolytic activity of the F1F0-ATPase complex even in 
presence of saturating oxygen concentration. 
Thus, to clarify the conflicting hypothesis on the role of IF1 in cancer cell 
bioenergetics, the activity of both the respiratory chain and the F1F0-ATPase 
complex were analyzed in both parental and IF1-silenced osteosarcoma cells. 
 
3- Bioenergetic changes in IF1-silenced clones 
IF1 overespression has been observed in many human carcinomas, but the 
few hypothesis put forward on the associated effects are highly controversial. 
Data in the literature report that IF1 not only inhibits ATPase activity, 
protecting from ATP depletion in response to respiration impairments, but it 
also defines the conformation of the ATP synthase and, consequentially, of 
mitochondrial cristae structure. In addition, it has been proposed that IF1 can 
regulate the oxidative phosphorylation under normal physiological 
conditions (136). 
Since the biochemical characterization of the IF1-depleted osteosarcoma cells 
revealed that in normoxic conditions the inhibitor was not involved in 
mitochondrial conformation (in terms of mass and network profile), nor in 
promoting cell proliferation, we decided to further investigate the role of the 
protein by measuring the oxygen consumption rate by the respiratory chain 
and the ATPase activity of the enzyme. 
  
3.1- Oxygen consumption rate 
The role of the inhibitor was further investigated by measuring the oxygen 
consumption rate of the cells through polarographic techniques. To that aim, 
cells were permeabilized with digitonin (60 µg/ml) and energized with the 
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substrates of Complex I, glutamate/malate, in the presence of malonate for 
inhibiting the enzyme succinate dehydrogenase (state 2 respiration). 
Subsequently, ADP was added to induce the state 3 respiration, and then the 
oligomycin, inhibitor of ATP synthase, to determine the onset of the state 4 
respiration. Figure 29 shows a representative graph of the oxygen 
consumption rate, in three functional states described above, in the parent 
cell line (black trace), the scrambled clone (blue trace) and the two silenced 
clones (red and magenta traces).  
 
 
 
Figure 29: Mitochondrial respiration changes in IF1-depleted cells.  
(A) Typical Complex I-driven oxygen consumption traces obtained in digitonin-
permeabilized cells after energizing mitochondria with glutamate/malate, followed by 
addition of ADP and oligomycin A. Parental (black line), scrambled (blue line), and IF1-
depleted cells (red and magenta lines) were represented. State 3 (B), state 4 (C), and 
uncoupled (D) respiration rate, expressed as nanomole of O2/min/mg of protein, were 
represented. Histograms show the mean ± S.D. of three independent experiments. *, p 
<0.05 indicates the statistical significance of data compared with both parental and 
scrambled cells. 
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As quantified in the graph (Figure 29, B), the removal of IF1 from the cells 
caused a modest (nearby 20%) but reproducible decrease State 3 respiration 
rate. However, no difference was registered in presence of Oligomycin (State 
4), indicating that the absence of the inhibitor did not affect the respiratory 
chain activity (Figure 29, C). 
Lastly, to check whether the functional alterations detected in the state 3 
respiration in the silenced clones had to be ascribed to a defect in the 
respiratory chain, or complex V of OXPHOS, the oxygen consumption rate 
was also measured in the presence of the uncoupler DNP, monitoring the 
maximum capability of oxygen consumption by the respiratory chain after 
removing the control that ATP synthase exerts on the electrons transfer 
(Figure 29, D). However, in these conditions, no difference was registered 
among the clones. 
 
3.2- OXPHOS  
Digitonin-permeabilized cells energized with substrates for Complex I 
revealed a decrease in State 3 respiration in absence of IF1. To verify if such 
difference was an effect of a different mechanism of action of the F1F0 ATP 
synthase in absence of the inhibitor, we first had to exclude any difference in 
the onset of the OXPHOS complexes. However, the immunodetection of 
OXPHOS complexes was unaltered in absence of IF1, as shown in Figure 30. 
Considering that the inhibitor has been extensively defined as an 
unidirectional valve, active to inhibit the hydrolysis, without affecting the 
ATP synthesis rate, these results were quite unexpected. Indeed, these data 
indicate that even in normoxic conditions – thus not predicted to favor the 
binding of IF1 to the ATP synthase - the presence of the inhibitor protein in 
osteosarcoma 143B cells can enhance the rate of ATP synthesis via OXPHOS, 
albeit not affecting the respiratory chain activity, yet increasing OXPHOS 
capacity to enhance ATP availability, when needed. 
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Figure 30: Immunodetection of OXPHOS complexes after SDS-PAGE separation 
synthase in parental, scrambled and IF1-depleted cells.  
(A) Typical electrophoretic separation and immunodetection of both OXPHOS complex 
subunits and porin in cell lysates obtained from controls and IF1-silenced cells.  
(B) Scanned images were quantitated by the Image Lab Software and data were 
normalized with respect to the porin content, taken as an internal standard. Relative 
protein levels of OXPHOS subunits were expressed as arbitrary units. The histograms 
show the mean value ± SD of two independent experiments. 
 
3.3- Mitochondrial membrane potential 
Given the different bioenergetic behavior of IF1 silenced cells compared to 
controls, we measured the ΔΨm of all cell types by examining the 
fluorescence of TMRM loaded cells. Consistent with the latter data, 
fluorescence microscopies after incubating 20 nM TMRM evidently proved 
that when IF1 was not expressed, cells displayed a higher ΔΨm across the 
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inner membrane, resulting in a greatest intensity of the TMRM fluorescence 
(Figure 31, A). 
These results were then confirmed and quantified by flow cytometry analysis 
and representative cells fluorescence distribution is reported in Figure 31, B: 
the fluorescence mean values of IF1 silenced cells resulted enhanced of nearly 
30% compared to controls, but such difference was nullified upon the 
addition of oligomycin (Figure 31, C), indicating that the endogenous steady-
state Δψm of the IF1 silenced cells was significantly increased compared to 
controls, but still far below to its maximum (i.e. upon oligomycin exposure of 
the cells). To note, no difference was found in the mitochondrial content of 
these cells, as indicated above (Figure 27).  
 
 
Figure 31: IF1 silencing enhances the mitochondrial membrane potential in 
human osteosarcoma cells.  
(A) Parental, scrambled, and IF1-depleted cells were loaded with 20 nM TMRM and 
fluorescence images were obtained using an inverted fluorescence microscope 
(magnification X40). (B) Flow cytometry analysis of cellular populations stained with 
TMRM, in the absence (yellow) or presence (brown) of oligomycin. (C) Histogram 
graph showing the flow cytometry semiquantitative evaluation of the mitochondrial 
membrane potential of controls and IF1-depleted cells in the absence (filled bars) or 
presence (dashed bars) of oligomycin. Bars show the mean ± S.D. of six independent 
experiments; **, p<0.01 indicates the statistical significance of data compared with 
controls.  
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To establish whether this difference in the bioenergetics of osteosarcoma 
cells among controls and –IF1 silenced cells was caused by a different 
mechanism of action of the enzyme, in presence and absence of the inhibitor, 
we analyzed the hydrolytic activity of the F1Fo ATP synthase in presence of 
saturating oxygen conditions. 
 
3.4- ATPase activity  
To verify whether the ATP hydrolysis rate of the ATP synthase complex 
showed similar behavior to those earlier reported, we tested the ATPase 
activity of our set of cells in isolated uncoupled mitochondria (Figure 32). As 
expected on the bases of previous results (135) and (137), the oligomycin 
sensitive ATPase activity (OS-ATPase) of mitochondria was pH-sensitive, 
being at pH 6.7 about half than at pH 7.4.   
 
 
 
Figure 32: Oligomycin-sensitive ATP hydrolysis activity measured in 
mitochondria isolated from controls and IF1-silenced clones.  
Mitochondria were isolated using different buffers at either pH 7.4 (filled bars) or 6.7 
(hashed bars) during the extraction procedure. Histograms showing the mean ± S.D. of 
three independent experiments. **, p< 0.01 and ##, p< 0.01 indicate the statistical 
significance of data compared with both parental and scrambled mitochondria, 
isolated at pH 7.4 and 6.7, respectively. 
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To note, the OS-ATPase activity of mitochondria from IF1 silenced cells 
resulted 2-3 fold and 4-5 fold higher than in controls at pH 7.4 and 6.7, 
respectively, in agreement with data reported by Cabezon et al.  (138).  
 
 
4- ROS and IF1 
Mitochondria are the major source of reactive oxygen species (ROS) and a 
target of oxidative damage during oxidative stress: initial investigations 
revealed that ROS can damage proteins, lipids, and DNA, thus considered 
tumorigenic factors inducing genomic instability. However, a recent 
paradigm shift has shown that mROS contributes to retrograde redox 
signaling from the organelle to the cytosol and nucleus, acting as signaling 
molecules to activate pro-growth responses and regulate cell cycle 
progression (64). Either way, intracellular ROS content must be regulated to 
avoid oxidative stress, and a number of defense mechanisms have evolved to 
provide a balance between production and removal of ROS in the cell. 
The role of IF1 in ROS production, content and effect is not clear, and requires 
further investigation.  
 
4.1 - Evaluation of intracellular ROS 
Although the role of mitochondria has been widely investigated, to clarify the 
role exerted by IF1 to bioenergetics and oxidative stress in the osteosarcoma 
cells, we measured the intracellular ROS content, through two different cell-
permeant dyes: CellROX® DeepRed and CellROX® Orange, analyzed by a 
FACSaria flow cytometer and Muse Cell Analyzer, respectively (Figure 33).  
As expected on the basis of data showed above, (i.e. lower state 3 respiration 
and a higher mitochondrial membrane potential in IF1-null osteosarcoma 
cells), both measures confirmed that ROS content was reduced in presence of 
the inhibitor, suggesting that IF1 may exert a protective role against ROS 
production and accumulation in osteosarcoma cells, reducing potential 
cellular damage.  
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Figure 33: Intracellular ROS content.  
Cells were harvested, washed once in PBS solution and loaded with 5 μM CellROX® 
Deep Red (A) or Orange (B) probes (Thermo Fisher Scientific) in complete medium 
without FBS for 30 minutes in the dark. Intracellular ROS content was then detected 
through FACSaria flow cytometer or with MuseTM Cell Analyzer, respectively. Parental 
(white bars), scrambled (grey bars), and IF1-depleted cells (black bars) were 
represented. Histograms show the mean ± S.D. of three independent experiments. *, p 
<0.05 indicates the statistical significance of data compared with both parental and 
scrambled cells. 
 
 
 
5- Dimerization of F1F0 ATP synthase and IF1 
Based on the conformation of the active form of the inhibitor, that 
simultaneously binds two distinct F1 portions of ATP synthase, many studies 
in the recent literature proposed that IF1 promotes the dimerization of the 
F1F0-ATPase (60), inducing the formation of mitochondrial cristae (59). This 
aspect has a particular relevance, since it has been proposed that IF1 defines 
mitochondrial volume fraction, regulates autophagy (63) and protect cancer 
cells from apoptosis (27), attributing a crucial role to the inhibitor for cancer 
progression.  
5.1 Distribution of monomers and oligomers of F1Fo-ATPase 
To assess whether IF1 influence the oligomerization of ATP synthase – 
consequently contributing to define mitochondrial volume and ultrastructure 
-  a comparative analysis was conducted, in both IF1-silenced and control 
cells, following a BN-PAGE electrophoretic separation of the digitonin-
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extracted proteins in the four lines of interest: Parental, scrambled and the 
two silenced clones A7 and D9. At first, the in-gel ATPase activity of the 
monomeric and oligomeric forms of the enzyme was analyzed and the assay 
clearly showed that both monomers and dimers were ATP hydrolysis 
competent (Figure 34). 
 
 
Figure 34: Representative in-gel activity staining of the monomeric and 
oligomeric ATP synthase.  
Proteins were extracted from digitonin-treated mitochondria from parental, 
scrambled, and IF1-depleted cells after BN-PAGE separation. 
 
 
Then, digitonin-extracted ATP synthase protein were transferred on a 
nitrocellulose membrane and immunolabeled with primary monoclonal 
antibody anti-α subunit of the ATP synthase to evaluate the distribution 
between monomers and dimers (Figure 35). As shown in the 
immunoblotting, and quantified by densitometric analysis of the bands, no 
difference was observed in the distribution of the monomeric and dimeric 
forms between the silenced cells and controls. Indeed, the monomeric form 
(black bar) ranges from 53 to 58% and the dimeric form (gray bar) from 42 
to 47%, suggesting that IF1 is not essential for ATP synthase dimerization, 
confirming data reported by Lippe G. and co-workers (62). 
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Figure 35: Distribution of monomeric and dimeric form of the F1Fo ATP synthase 
in presence or absence of IF1.  
(A) Monomeric and oligomeric distribution analysis of the ATP synthase performed by 
immunodetection of the F1 α-subunit after separation of the proteins by BN-PAGE, 
followed by blotting of the native complexes onto nitrocellulose membrane.  
(B) Histograms represent the densitometric analysis of the monomer (dark bar) and 
dimer (gray bar) of the ATP synthase complex. The representative data were 
confirmed in three independent experiments. 
 
5.2  IF1 binds to the dimeric form of ATP synthase 
As well established by Walker, IF1 can exist as an active dimer or inactive 
oligomer, depending on the aqueous phase pH: at pH lower than 6.5 the 
equilibrium is forced towards the active form of the inhibitor and the F1-ATP 
hydrolytic activity fully inhibited; conversely, when pH is around 8, or higher, 
IF1 is predominantly oligomeric and inactive (138). 
Noteworthy, the immunodetection of the inhibitor protein in the four lines 
reveled that, even under normoxic conditions, the inhibitor protein was 
associated to the ATP synthase: to note, this is quite intriguing, since IF1 
should not affect F1F0-ATPase in these conditions. Moreover, more than 90% 
of the inhibitor was found to be localized in correspondence of the dimers of 
ATP synthase (Figure 36) in both controls (i.e. parent and scrambled cells),  
indicating that the main target of IF1 is the dimeric form of the ATP synthase 
(obviously, no IF1 bands were detected in correspondence of the silenced 
cloned).  
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Figure 36: IF1 binds exclusively to the dimeric form of ATP synthase. 
Immunodetection of IF1 was performed after separation of dimeric and monomeric 
ATP synthase by BN-PAGE (3.5–7% gradient) followed by blotting onto nitrocellulose 
membrane. A shown, IF1 almost entirely binds to the dimeric form of ATP synthase. As 
expected, no bands were detected in correspondence of the IF1-silenced clones. 
 
Overall, these data suggest that the inhibitor does not influence ATP synthase 
dimerization, that occurs independently from IF1; however, we can speculate 
that the inhibitor protein may have a role in stabilize the dimeric form of ATP 
synthase, thus increasing the activity of the enzyme, resulting in a higher 
mitochondrial membrane potential and lower respiration rate in the IF1-null 
cells with respect to controls, as showed above.  
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Results – 2nd part: miRNAs 
 
6- miRNAs profiling pattern of expression in cancer 
MicroRNAs deregulation in cancer was first demonstrated in 2002 (7), 
opening a new branch of investigation over cancer related issues. Since then, 
increasing studies have showed that microRNAs play important roles in 
tumor growth, by regulating oncogenes and tumor suppressor genes (139), 
and that cancer metabolism is greatly modulated by epigenetic alterations 
through miRNAs (140), stimulating researchers to address the connection 
between specific miRNAs and cancer metabolism. Thus far, accumulating 
studies indicate that many miRNAs affect the expression of key genes 
involved in glycolysis and energy metabolism, underlying the importance of 
improve our knowledge over these small molecules, to further elucidate the 
modulation of metabolic pathways in cancer cells and, far beyond, to assess 
potential new therapeutic targets - or agents - in cancers. 
In order to assess microRNAs contribution to modulate cancer metabolism, 
an analysis of the miRNAs expression pattern was performed (data not 
shown). Among the lines screened, a sensitive- and a resistant-to BRAF-I 
treatment melanoma cell lines (i.e. M21 and M21-R melanoma cells) were 
included. Of note, we found that resistant cells displayed an up-regulation of 
four miRNAs when compared to the sensitive ones. Much more intriguingly, 
three out of four of these miRNAs were predicted to target SUFU, the negative 
regulator of development-related Shh pathway, which has been proved to be 
altered in various forms of cancer (94). Therefore, these compelling data 
pushed us to further investigate over the connection between miRNAs 
expression and refractory to treatment, pointing towards the need for novel 
and more innovative therapeutic approaches to by-pass anticancer drug 
resistance in yet poor prognosis malignancies. 
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6.1 Validation of miRNAs overexpression in resistant cells 
Among the four miRNAs, miR-136 displayed the highest expression, resulting 
in a remarkable over-expression in M21 resistant cells (i.e. M21-R) with 
respect to the sensitive ones, encouraging us to primarily focus on the role 
exerted by this microRNA. However, to better elucidate this aspect, two other 
melanoma cell lines (both sensitive and resistant types) were included in the 
study, to validate the microarray data through a q-RT-PCR (Figure 37).  
 
 
 
Figure 37: miR-136 is over-expressed in melanoma BRAF-I resistant cells with 
respect to sensitive cells. Upon cells harvesting, RNA was extracted and retro-
transcribed, then expression analysis of  miR-136 and the small nuclear U6  was 
performed, with TaqMan primers and probes (Life Technologies). Bars represent FC 
miR136 upon U6 expression, used as miRNA internal control, in BRAF-I resistant (black 
bars) and sensitive (white bars) cells of three different melanoma cell lines: M21 (A), 
Colo38 (B) and SK-Mel-37 (C). Histograms show the mean ± S.D. of three independent 
experiments. ***, p <0.005 and ****, p<0.0005 indicate the statistical significance of 
resistant cells data compared to BRAF-I sensitive cells. 
 
 
Quantitative Real-Time PCR confirmed the microarray data in all the cell lines 
tested, revealing that miR-136 is greatly expressed in BRAF-I resistant 
melanoma cells when compared to sensitive to treatment cells of the same 
type. The inhibitor of the Shh pathway, SUFU, was found to be a common 
target of three out of the four overexpressed microRNAs, leading to the 
analysis of the inhibitor in these cells. 
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6.2 SUFU is down-regulated in resistant cells 
On the bases of the algorithm used by some miRNA databases, miR136 was 
predicted to target SUFU, the negative regulator of Shh pathway. Therefore, 
once assessed miR-136 overexpression in the resistant cells, we then 
screened four lines for the expression of SUFU. To that aim, an SDS-PAGE was 
performed, and electrophoretically separated proteins were electroblotted 
onto a nitrocellulose membrane, to be labeled with a rabbit monoclonal 
primary antibody against SUFU (Figure 38). 
 
  
Figure 38: Assessment of SUFU expression in melanoma cells. 
Lysed cells were separated by SDS-PAGE and electroblotted onto a nitrocellulose 
membrane. SUFU levels were assessed after incubating the membranes in the presence 
of rabbit primary monoclonal antibody, over β-Actin (Cell Signaling). The histogram 
below represent the quantification of the bands: results of three independent 
experiments are expressed as the mean value ±SD of sensitive (white bars) and 
resistant (black bars) melanoma cells: M21 (A) and Colo38 (B). ***p<0.005 
 
As shown in the immunoblot, both M21-R and Colo38-R were characterized 
by a lower expression of SUFU, yet significant and reproducible (quantified in 
25% and 33% reduction, respectively) in both cell lines tested, as 
represented in the densitometric analysis below. To further confirm whether 
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this reduction was able to induce the activation of the Shh pathway, the 
activity of this pathway in sensitive and resistant melanoma cells was also 
determined. 
 
6.3 SHH pathway activation 
Shh pathway has been proved to be deregulated in various types of cancer; 
moreover, a recent paper reported that melanoma resistance to BRAF-I is 
mediated by Shh alteration through PDGFRα up-regulation (106). Since we 
showed that the negative regulator of the pathway downregulated in the 
BRAF-I resistant melanoma cells, we proceeded by measuring the activity of 
Shh pathway through a Dual Luciferase Gene reporter assay. To that aim, 
eight repeated copies of wild-type or mutated Gli-binding sites (3’GliBS or 
mut3’Gli-BS, respectively) were cloned into a psi-check2 vector (Promega), 
thus controlling the activity of a Firefly Luciferase (Photinus pyralis). 
Together with this reporter gene, cells were also co-transfected with a pRLTK 
vector, a wild type Renilla luciferase (Renilla reniformis, also known as sea 
pansy) control reporter vector, to normalize the expression of the 
experimental firefly luciferase reporter gene.  
 
Figure 39: Shh pathway activity. 
Adherent melanoma cells were co-transfected with a Firefly luciferase reporter gene 
together with a pRLTK Reporter Vector, used as an internal control. After rinse in PBS, 
cells were lysed for 15 minutes RT and ratios between Firefly and Renilla luciferase 
activity were estimated using a GloMax® 96 Microplate Luminometer (Promega). 
Histograms show the mean ± S.D. of three independent experiments. ***, p< 0.01 and 
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p<0,0001 indicates the statistical significance of Firefly/Renilla activity in the BRAF-I 
resistant cells compared to BRAF-I sensitive cells. 
 
As shown in Figure 39, Shh pathway activity was greatly enhanced in both 
resistant cell lines, with respect to BRAF-I sensitive cells, indicating that the 
reduction of SUFU expression (25% and 33% in M21-R and Colo38-R 
respectively, as presented above) was sufficient to induce Shh activation, 
eventually resulting in a higher proneness of melanoma cells to proliferate, 
thus counteracting the treatment with BRAF-I. 
 
7- Variation of miR-136 expression 
On these premises, to investigate the mechanisms underlying miR-136 
contribution in triggering acquired BRAF-I resistance in melanoma cells, we 
then proceeded verifying the cellular response to a miR-136 modulation. 
Sensitive melanoma cells were transfected with miR-136 mimic molecules, 
small, chemically modified double-stranded RNA that mimic endogenous 
miRNAs, thus enabling miRNA functional analysis by the up-regulation of 
miRNA activity. Conversely, miR-136 was downregulated in the BRAF-I 
resistant cells, by means of miR-136 inhibitors (α-miR-136), single-stranded 
RNA molecules targeting (and inhibiting) the corresponding endogenous 
miRNAs. In both cases, a scrambled mimic RNA was used as a negative 
control. 
After transfection, upon miR-136 levels assessment each time point 
considered, SUFU expression and the Shh pathway activation were evaluated. 
Furthermore, basing on the hypothesis that miR-136 would lead to BRAF-I 
resistance in melanoma cells, cell growth assays were performed under 
vemurafenib (i.e. BRAF-I PLX4032) treatment, following miR-136 up- or 
down-regulation, in BRAF-I sensitive and resistant cells, respectively. 
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7.1- SUFU  
SUFU expression was first evaluated in M21 and M21-R cells, upon miR-136 
transfection: following miR-136 levels increase in sensitive cells, SUFU was 
found to be reduced; conversely, enhanced content of the microRNA in the 
BRAF-I resistant cells (displaying a greater amount of miR-136 in wild type 
conditions with respect to the sensitive ones) had no substantial effect on the 
expression of the protein (Figure 40). To note, SUFU levels in the sensitive 
cells settled on the same levels exhibited by resistant cells in wild type 
conditions, again confirming that the expression of the inhibitor of Shh 
pathway and miR-136 were related. 
 
 
 
 
Figure 40: SUFU is reduced in melanoma sensitive cells when miR-136 levels are 
increased. BRAF-I sensitive melanoma cells were seeded and transfected either with 
scrambled or miR-136 mimic for 24 hours. Lysed cells were separated by SDS-PAGE 
and electroblotted onto a nitrocellulose membrane. SUFU levels were assessed 
immunolabelling protein bands with a rabbit primary monoclonal antibody (Cell 
Signaling). The histograms below represent the densitometric analysis of the bands, 
normalized over β-Actin (Cell Signaling). Results of three independent experiments are 
expressed as the mean value ±SD in sensitive (white bars) and resistant (black bars) 
M21 melanoma cells. ***p<0.005 indicates the statistical significance of miR-136 
transfected cells compared to scrambled transfected ones. 
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Once determined this association, we explored the consequences of 
increasing miR-136 in the sensitive cells of both cell lines, following the 
expression of SUFU up to 96 hours after transfection either with scrambled 
or miR-136 mimics. As expected on the basis of previous results, SUFU 
rapidly decreased its expression upon miR-136 transfection in the sensitive 
cells, resulting in about 25 and 50% of reduction in the first 24 and 48 hours, 
in both cell lines (Figure 41).  
 
 
 
Figure 41: SUFU trend upon miR-136 transfection. 
BRAF-I sensitive melanoma cells were seeded and transfected either with scrambled or 
miR-136 mimic for up to 96 hours. Lysed cells were separated by SDS-PAGE and 
electroblotted onto a nitrocellulose membrane. SUFU levels were assessed 
immunolabelling protein bands with a rabbit primary monoclonal antibody (Cell 
Signaling). The histograms below represent the densitometric analysis of the bands, 
normalized over β-Actin (Cell Signaling). Results of two independent experiments are 
expressed as the mean value ±SD in scrambled (white bars) and miR-136 (dashed bars) 
M21 (A) and Colo38 (B) melanoma cells.  
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To note, following 48 hours from transfection most of the exogenous 
microRNA was degraded inside the cells (data not shown), likely explaining 
why SUFU started to increase again after 72 hours since transfection, being 
almost the same between scrambled and miR-136 transfected at 96h.  
However, these results clearly evidenced that varying miR-136 content, SUFU 
was - in turn - modulated as well, thus confirming that these molecules can 
play a crucial role in triggering resistance mechanisms to BRAF-I in 
melanoma cells. 
 
7.2- SHH pathway 
SUFU trend assessment upon miR-136 modulation was paralleled by the Shh 
activity evaluation, through the Dual Luciferase assay, to verify if the 
variation in miR-136 content was affecting the activity of the pathway by 
modulating the expression of its inhibitor. To double check this association, 
analysis were performed in both M21 (Figure 42) and M21-R (Figure 43) cells 
after transfection with miR-136 and α-miR-136, respectively. 
 
 
Figure 42: Shh activation upon miR-136 transfection in sensitive cells 
Adherent melanoma cells were co-transfected with a Firefly luciferase Shh pathway 
activity reporter gene, together with a pRLTK Reporter Vector, used as an internal 
control. After rinse in PBS, cells were lysed for 15 minutes RT and ratios between 
Firefly and Renilla luciferase activity were estimated using a GloMax® 96 Microplate 
Luminometer (Promega). Histograms show the mean ± S.D. of three independent 
experiments. **, p< 0.01, ***, p <0.001 and ****, p<0,0001 indicate the statistical 
significance of Firefly/Renilla activity in the BRAF-I resistant cells compared to BRAF-I 
sensitive cells. 
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Figure 43: Shh activity is reduced when SUFU is increased in resistant cells by 
inhibiting miR-136 
Adherent melanoma cells were co-transfected with a Firefly luciferase Shh pathway 
activity reporter gene, together with a pRLTK Reporter Vector, used as an internal 
control. After rinse in PBS, cells were lysed for 15 minutes RT and ratios between 
Firefly and Renilla luciferase activity were estimated using a GloMax® 96 Microplate 
Luminometer (Promega). Histograms show the mean ± S.D. of three independent 
experiments. **, p<0.01 and ***, p<0,0001 indicate the statistical significance of 
Firefly/Renilla activity in the BRAF-I resistant cells compared to BRAF-I sensitive cells. 
 
 
Figures 42 shows that miR-136 transfection in M21 sensitive melanoma cells 
induced Shh activation, with a greatly enhanced activity in the first 24 hours 
post transfection with respect to scrambled controls, and the pathway was 
still highly active after 48 hours. Coherently, when the miR was inhibited Shh 
activity was reduced, as expected on the basis of the increased levels of SUFU 
(Figure 43). 
To note, as specified above, after 72h since transfection, most of the 
exogenous miRNAs were degraded inside the cells, thus explaining why the 
Shh activity in the sensitive cells was decreased at this point. 
Overall, it seemed reasonably to conclude that the Shh pathway is activated 
by the enhanced expression of miR-136, that induce a downregulation of its 
inhibitor SUFU, therefore pushing BRAF-I resistant melanoma cells to 
overcome the effect of the drug itself and proliferate, aggressively and 
uncontrollably.  
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7.3- Cell growth evaluation 
BRAF-I resistance has been showed to be mediated by Shh pathway 
activation (106), leading to a massive and aggressive proliferation of 
melanoma cells when developing resistance to vemurafenib. Since we 
showed that miR-136 was up-regulated in melanoma resistant cells, inducing 
a reduction in the expression of SUFU, the negative regulator of the Shh 
pathway, we hypothesized that an increase in miR-136 levels in sensitive 
melanoma cells would trigger some molecular mechanisms, eventually 
protecting these cells from the effect of the drug. Conversely, we assumed 
that the inhibition of  miR-136 in BRAF-I resistant cells could restore, at least 
partially, sensitivity to the drug. 
To verify such hypothesis, miR-136 transfected melanoma sensitive cells 
M21 were transfected either with scrambled or miR-136 and treated with 0,5 
µM vemurafenib, following the cell growth for up to 120 hours (A); in 
addition, the same experiment was performed on Colo38 cells, transfecting 
sensitive cells with the same amount of microRNA, but increasing the amount 
of drug (B). To note, since the endogenous microRNAs (both mimics and 
inhibitors) were rapidly degraded inside the cells, transfection procedures 
were repeated between 48 and 72 hours, in order to maintain high or low 
levels of miR-136 inside the cells.  
 
A 
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Figure 44: Cell growth under BRAF-I treatment upon miR-136 transfection in 
BRAF-I sensitive melanoma cells. 
Cells were seeded in 6-wells plates and transfected with 50 nM either of scrambled 
(grey lines) or miR-136 mimics (black lines). After 24h from transfection, cells were 
treated with 0,5 µM (M21, panel A) or 6 µM (Colo38, panel B) of PLX4032 
(Vemurafenib, BRAF-I) and grown for up to 120h. Proliferation rate was assessed every 
day, collecting all the cells in the plates. Results are represented as the mean of each 
time point ± SD of three independent experiments. 
 
 
As shown, both M21 and Colo38 melanoma cells proliferated more in 
presence of miR-136, with respect to the scrambled transfected cells: 
particularly, after 120h after treatment with 0,5 µM miR-136 transfected 
M21 cells were still able to proliferate (Figure 44, A), whereas the 
corresponding scrambled transfected were almost arrested. The lower – yet 
significant - effect showed in Colo38 cells (Figure 44, B) has to be ascribed to 
the higher concentration of the drug, which was critical for both scrambled 
and miR136 transfected cells after 96h of treatment: however, even in these 
critical conditions, a protective role exerted by miR-136 was observed.  
Coherently, we hypothesized that inhibiting miR-136, through its inhibitor, 
could restore the sensitivity to BRAF-I in resistant melanoma cells. Therefore, 
M21-R and Colo38-R were transfected with 50 nM of the anti-miR-136 and 
followed for up to 120 hours after transfection, using scrambled transfected 
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cells as control (Figure 45). Again, transfection procedures were repeated 
every 48 hours, in order to keep low levels of miR-136 inside the cells. 
 
 
Figure 45: Inhibit miR-136 restore sensitivity to BRAF-I in melanoma resistant 
cells. 
Cells were seeded in 6-wells plates and transfected with 50 nM either of scrambled 
(grey lines) or α-miR-136 (black lines), while treated with 0,5 µM (M21-R, panel A) or 
6 µM (Colo38-R, panel B) of PLX4032 (Vemurafenib, BRAF-I). Grown for up to 120h, 
proliferation rate was assessed every day, collecting all the cells in the plates. Results 
are represented as the mean of each time point ± SD of three independent experiments. 
 
As shown in the graphs above, cell proliferation rate was diminished in 
melanoma resistant to BRAF-I cells when miR-136 was inhibited, 
suggesting that miR-136 is a crucial element to trigger and maintain 
resistance to therapy in these cells. 
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8- The effect of BRAF-I treatment on melanoma cells 
expression 
Once assessed the interconnection between miR-136 and SUFU, we 
wanted to explore whether vemurafenib treatment could affect one of 
these parameters in melanoma cells. To that extent, melanoma BRAF-I 
sensitive cells were treated with PLX4032, whereas resistant-to-treatment 
cells were temporarily deprived of the drug, in order to evaluate cell 
growth, SUFU expression and, more importantly, miR-136 levels. 
 
8.1- BRAF-I decreases proliferation rate in melanoma cells 
Melanoma M21 cells were treated with different concentration of BRAF-I and 
cell growth was assessed after 24 (Figure 46, A) and 96 (Figure 46, B) hours 
after treatment.  
 
A           B 
 
Figure 46: Cell growth evaluation upon increasing dose of vemurafenib 
in melanoma BRAF-I sensitive M21 cells. 
Melanoma M21 cells were treated with increasing amount of vemurafenib and 
cell growth was assessed after 24h (A) and 96h (B) of treatment. Results were 
represented as the mean ± SD of three independent experiments.  
 
 
As expected, on the basis of vemurafenib treatment in melanoma patients, 
cell proliferation rate was extremely sensitive to the drug, resulting in a dose-
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dependent reduction in cell growth. Specifically, a great decline was observed 
after prolonged time of treatment in M21 melanoma cells.  
Conversely, a comparison between sensitive and BRAF-I resistant cells at two 
different amount of the drug, showed that BRAF-I resistant M21-R cells were 
obviously not affected by increasing amount of the drug, contrarily to the 
sensitive ones, thus confirming the time- and dose-dependent effect in the 
proliferation rate of melanoma BRAF-I sensitive cells in presence of the drug 
(Figure 47).  
 
A              B 
 
 
Figure 47: Comparison between BRAF-I sensitive (M21, A) and resistant (M21-R, 
B) melanoma cells under two different amount of vemurafenib treatment. 
Melanoma M21 and M21-R cells were treated with 0,5 µM (A) and 1 µM (B) of 
PLX4032 (vemurafenib, BRAF-I) and cell growth was assessed after 72h of treatment 
in both cell lines. Results were represented as the mean ± SD of three independent 
experiments.  
 
 
In these conditions, the expression of SUFU and the activity of Shh pathway 
were determined in BRAF-I sensitive melanoma cell lines, comparing them 
with miR-136 levels upon vemurafenib treatment. 
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8.2- BRAF-I effect in sensitive melanoma cells 
BRAF-I sensitive melanoma cells were exposed to vemurafenib for prolonged 
time and the above-discussed parameters were determined. Specifically, M21 
and Colo38 cells were treated with 0,5 µM BRAF-I for 72 hours and the 
expression of SUFU was assessed every 24h: then, the drug was removed and 
cells were followed up for additional 72 hours. 
 
A 
 
B 
 
Figure 48: SUFU expression upon vemurafenib treatment in BRAF-I 
sensitive melanoma cells 
BRAF-I sensitive melanoma cells (M21, A and Colo38, B) were cultured in 
presence of 0,5 µM vemurafenib for 72 hours and then cells were grown for 
additional 72h after removal. Lysed cells were then separated by SDS-PAGE 
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and proteins were electroblotted onto a nitrocellulose membrane to be labeled 
with a rabbit monoclonal primary antibody against SUFU (Cell Signaling). 
SUFU expression was assessed very 24h and normalized over β-Actin 
expression (Cell Signaling). Densitometric analysis were performed and 
showed as the mean value ±SD in M21 (A) and Colo38 (B) melanoma cells in 
presence (dashed bars) and absence (white bars) of the drug. 
 
 
Surprisingly, vemurafenib treatment results in a gradual and time-dependent 
decrease of SUFU in both BRAF-I sensitive melanoma cell lines, M21 (Figure 
48, A) and Colo38 (Figure 48, B).  
Since we previously demonstrated that SUFU and miR-136 were related, we 
extracted RNA from these cells, in order to assess miR-136 levels by means of 
q-RT-PCR (Figure 49).  
 
 
Figure 49: miR-136 levels in BRAF-I sensitive melanoma cells treated with 
vemurafenib. 
BRAF-I sensitive melanoma cells (M21, A and Colo38, B) were cultured in presence of 
0,5 µM vemurafenib for 72 hours and then cells were grown for additional 72h after 
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removal. Upon cells harvesting, RNA was extracted and retro-transcribed, to assess 
miR-136 levels, with TaqMan primers and probes (Life Technologies). Bars represent 
FC of miR136 upon U6 expression, used as miRNA internal control in BRAF-I sensitive 
melanoma M21 (A) and Colo38 (B) cells in presence (filled bars) or absence (white 
bars) of BRAF-I (vemurafenib). Histograms show the mean ± S.D. of three independent 
experiments. **, p <0.01 and ***, p<0.001 indicate the statistical significance of BRAF-I 
sensitive melanoma treated cells compared to controls. 
 
 
As expected on the basis of previous results, showing that miR-136 and the 
inhibitor of Shh pathway are related, the down-regulation of SUFU following 
vemurafenib treatment in BRAF-I treated melanoma sensitive cells, was a 
consequence of increased levels of miR-136 upon treatment. Therefore, the 
activation of Shh pathway upon the treatment was confirmed in these cells. 
 
 
  
 
Figure 50: Shh activation in BRAF-I sensitive cells upon BRAF-I treatment. 
BRAF-I sensitive melanoma cells (M21 and Colo38 cells) were cultured in presence 
(dashed bars) or absence (white bars) of 0,5 µM vemurafenib for 72 hours. 
Concomitantly, adherent melanoma cells were co-transfected with a Firefly luciferase 
reporter gene together with a pRLTK Reporter Vector, used as an internal control. 
After rinse in PBS, cells were lysed for 15 minutes RT and ratios between Firefly and 
Renilla luciferase activity were estimated using a GloMax® 96 Microplate 
Luminometer (Promega). Histograms show the mean ± S.D. of three independent 
experiments. ***, p< 0.001 indicates the statistical significance of Firefly/Renilla 
activity in the BRAF-I resistant cells compared to BRAF-I sensitive cells. 
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To note, the Shh pathway was activated by BRAF-I treatment in sensitive-to-
treatment melanoma cells, whereas untreated cells showed no alteration in 
the pathway, as shown in Figure 50. 
Quite unexpectedly, these preliminary data indicated that vemurafenib 
treatment induced an overexpression of miR-136 in BRAF-I sensitive 
melanoma cells, eventually resulting in a lowered expression of SUFU that 
activates Shh pathway. However, to verify such connection between the 
treatment with BRAF-I, these parameters were also evaluated in BRAF-I 
resistant cells after removal of the drug. 
 
 
8.2- BRAF-I resistant cells upon removal of the drug 
To double confirm the effect of BRAF-I treatment on melanoma cells, levels of 
miR-136 and the expression of SUFU were evaluated in BRAF-I resistant cells 
upon removal of the treatment in these cells. 
 
A 
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B 
 
Figure 51: SUFU expression in BRAF-I resistant cells upon removal of 
vemurafenib. 
Vemurafenib was removed for 72 hours in BRAF-I resistant melanoma cells (M21-R, A 
and Colo38-R, B) and then re-introduced for further 72h. Lysed cells were then 
separated by SDS-PAGE and proteins were electroblotted onto a nitrocellulose 
membrane to be labeled with a rabbit monoclonal primary antibody against SUFU 
(Cell Signaling), whose expression was assessed very 24h and normalized over β-Actin 
expression (Cell Signaling). Densitometric analysis were represented as the mean value 
±SD in M21-R (A) and Colo38-R (B) melanoma cells in presence (black bars) and 
absence (grey bars) of the drug. 
 
 
 
Figure 52: miR-136 expression in BRAF-I resistant melanoma cells after removal 
of vemurafenib (BRAF-I). 
Vemurafenib was removed for 72 hours in BRAF-I resistant 21-R melanoma cells and 
then re-introduced for further 72h. Upon cells harvesting, RNA was extracted and 
retro-transcribed, to assess miR-136 levels, with TaqMan primers and probes (Life 
Technologies). Bars represent FC of miR136 upon U6 expression, used as miRNA 
internal control in BRAF-I resistant M21-R cells in presence (black bars) or absence 
(grey bars) of BRAF-I (vemurafenib). Histograms show the mean ± S.D. of three 
*** 
*** *** 
*** 
*** 
*** 
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independent experiments. ***, p<0.0001 was the statistical significance of resistant 
cells data after removal of BRAF-I compared to wild type cells. 
 
 
Overall, these preliminary data clearly indicate that vemurafenib itself 
induces an overexpression of miR-136 in melanoma cells, while sustaining its 
expression in BRAF-I resistant cells, allowing the mechanisms of resistance to 
therapy to take place. Actually, the overexpression of miR-136 triggers a 
domino effect resulting in a lowered expression of SUFU that – in turn – 
activates Shh pathway, leading to uncontrolled proliferation of BRAF-I 
resistant melanoma cells.  
On the basis of the effect of vemurafenib against melanomas, as proven by 
many clinical trials that lead to define vemurafenib as the drug of choice to 
cure metastatic BRAF(V600E)-carrying melanoma patients, these emerging 
data were not expected. Nonetheless, although the mechanism of microRNA-
mediated drug resistance is not fully understood, these emerging results 
could offer new perspectives to investigate over resistance to cancer therapy, 
that still accounts for death in over 90% of patients with metastatic cancers, 
due to therapeutic failure. Indeed, if the overexpression of miR-136 
effectively triggers drug-resistance in these cells, it is quite conceivable to 
believe that the therapy itself can mediate these mechanisms, inevitably 
leading to BRAF-I resistance in patients. Therefore, in this view, new 
therapeutic strategies could be considered to approach metastatic 
melanomas to counteract these mechanisms, potentially offering new 
chances of survival in yet poor prognosis patients. 
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Discussion and conclusions 
 
Tumor cells exhibit profound genetic, biochemical and histological difference 
with respect to the non-transformed cells of the same origin. Considering the 
master role of mitochondria inside the cells, an increasing number of human 
diseases is now correlated with mitochondrial alterations, both 
morphologically and functionally, including neurodegenerative diseases and 
cancer (10). Numerous studies conducted in the last decade, indeed, clearly 
indicate that mitochondrial dysfunctions are one of the most recurrent 
characteristics in cancer cells, as proven by microscopic and genetic 
alterations, as well as by biochemical and molecular analysis. 
Particularly, the literature over the last decade has been abundantly focusing 
on cancer metabolism, since many evidence reported that transformed cells 
are characterized by a glycolytic predominant phenotype: although the 
oxidative phosphorylation physiologically provides the major contribute to 
the ATP supply in normal cells – and yet in many cancer cell types - plenty of 
data reported a higher glucose consumption in the transformed cells, 
suggesting that a metabolic reprogramming occurs during malignant 
progression. Therefore, an increasing attention is now given to clarify which 
molecular mechanism modify energy metabolism in cancer cells, aiming to 
identify and inhibit one or more enzymes that play a key role in controlling 
metabolic alterations, in the hopes of possibly developing new potential 
therapeutic approaches. 
As reported by the literature, different biochemical mechanism may 
contribute to increase glycolysis rate in tumor cells, including the over-
expression of glycolytic enzymes and transporters, cellular adaptation to the 
hypoxic microenvironment within tumor - through HIF-1 mediated pathways 
- mutations in somatic genes, as well as epigenetic alterations, that drive 
cellular reprogramming in the altered tumoral scenario. Interestingly, it has 
been recently showed that the endogenous inhibitor protein of the ATP 
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synthase (IF1) is overexpressed in many human carcinomas: in a comparative 
study between healthy and cancer tissues, Cuezva and co-workers showed 
that the expression of the protein markedly increased in tumor cells, along 
with a number of metabolic features that are typically accounted in cancer 
cells, thereby suggesting that IF1 may have an important role in tumor 
progression (65). Since then, a number of papers speculated over possible 
roles of IF1 in the establishment of the so-called “cancer hallmarks”, 
hypothesizing that the inhibitor may act as a molecular switch of cancer 
metabolism, sustain cell growth in hostile conditions, mediate mechanism to 
escape apoptosis, further then being involved in the dimerization of the ATP 
synthase, thereby contributing in modifying mitochondrial structure and, 
hence, size and shape of mitochondria. Nevertheless, many of these issues are 
highly debated and no clear evidence has been yet provided to define how IF1 
may contribute in tumor progression, prompting our group to further 
investigate over this protein and its role in cancer.  
As it is well established, the inhibitor protein is the master regulator of the 
ATP hydrolytic activity of the ATP synthase: when the electrochemical 
gradient across the mitochondrial inner membrane collapses and is 
insufficient to drive ATP synthesis - as in hypoxia/ischemia, or in general 
when mitochondrial respiration is compromised - the ATP synthase reverses 
its function and hydrolyses ATP to restore the membrane potential, thus 
ensuring that all the mitochondrial-potential-related process take place. 
Simultaneously, under these conditions, cell energy metabolism is shifted 
toward glycolysis, and the resulting mitochondrial pH decreases, allowing the 
activation and the binding of IF1 to F1-ATPase domain (at the αE/βE 
interface), to avoid a massive glycolytic ATP depletion and protect cells from 
death. On this basis, it has been hypothesized that IF1 could play a key role in 
preventing energy dissipation when tumor cells experience hypoxic 
conditions, thereby promoting cell growth and survival.  
To better elucidate this aspect, some recent investigations have set out to 
explore the functional consequences of varying IF1 expression levels in 
different cancer cell lines. However, nearly all studies reported were 
 Simona Barbato Pag. 106 
 
performed in normoxic conditions and, more importantly, through transient 
IF1 over-expression or silencing: these transient models do not allow long-
term changes to be studied and may also produce potentially ambiguous 
biochemical data, often misleading interpretations and creating conflicting 
data, as reported. Transient modifications of the inhibitor, indeed, only refer 
to heterogeneous populations of cells (due to the coexistence of transfected 
and control cells), in a dynamic situation in which cells are adapting to the 
change in IF1 content.  
Given these restrictions, we prepared IF1-silenced clones from the human 
osteosarcoma 143B cell line and assayed the main bioenergetic parameters, 
to examine in stable IF1-silenced human osteosarcoma cells both the role 
played by IF1 and the mechanism the inhibitor adopts in tumor cells to 
control mitochondrial mass, structure and function, as well as to regulate 
energy homeostasis.  
Short hairpin RNAs are great experimental tools for inducing gene silencing 
in mammalian somatic cells: under the control of a constitutive expressed 
promotor, IF1-targeting-shRNAs ensured a permanent silencing of the 
protein, resulting in more than 90-95% of gene silencing in all the clones we 
used for our experiments, without altering cell morphology, nor the adhesion 
capacity of transfected cells, with respect to parent cells. In addition, both 
flow cytometry and fluorescence microscopy revealed that our systems were 
homogeneous, resulting in 99% of GFP expression – being GFP encoded in 
the plasmid we used for transfection – even after two years of cell culturing, 
along with the reduced expression of the inhibitor, confirming the stability of 
transfection. 
As we herein showed and recently reported (115), under normal conditions 
(i.e. normoxia) IF1-silenced cells proliferate normally, consume glucose and 
release lactate as controls do. On the basis of earlier studies on both isolated 
mitochondria and submitochondrial particles (135) and (134), these results 
were quite expected, since the inhibitor protein is not supposed to inhibit the 
ATP hydrolytic activity of the enzyme in normoxia. Coherently, analysis on 
stable IF1-depleted HeLa cells reported by Fujikawa et al. (131) are in line 
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with our results, but were debated by other groups showing that IF1 
promotes cell growth and progression in transiently-transfected tumor cells 
(these data were collected in normoxic conditions, that do not favor binding 
of IF1 to the F1Fo-ATPase complex), inducing us to suppose that transient 
models do not properly represent a stable steady-state metabolic condition.  
IF1 overexpression have been proposed to promote tumor progression by 
either reducing mitochondrial ATP synthase activity and increasing aerobic 
glycolysis (132), or inducing a ΔΨm decrease that is associated with enhanced 
proneness to apoptotic cell death by cytochrome c release from mitochondria 
(27).  In our model, we showed that IF1-silenced cells intriguingly displayed 
an enhanced steady-state mitochondrial membrane potential, consistent with 
the higher ΔΨm reported by Fujikawa et al., along with a reduced ADP-
stimulated respiration rate (incidentally, this reduction was not observed 
either in state 4, or in dinitrophenol uncoupled conditions), over the same 
OXPHOS content presented in all the cells. Moreover, we here showed that IF1 
exerts a protective role against ROS production, protecting cancer cells from 
ROS-related damages. 
However, these data are in contrast with those reported by Sanchez-Cenizo et 
al. (65), who reported an increase in ΔΨm in transiently-overexpressing-IF1 
carcinoma cells, paralleled by retrograde ROS signal to the nucleus triggered 
by superoxide radical to support tumor development through the NF-κB.  
Although we cannot exclude that different types of cancer cells behave 
differently from HeLa (131) (59) and osteosarcoma cells, we still believe that 
some of these latter results may be only apparent, due to the analysis of an 
heterogeneous population of cells, with different IF1 expression levels.  
Taken together, overall data indicate that the presence of the inhibitor 
protein in osteosarcoma 143B cells can enhance the rate of ATP synthesis via 
OXPHOS, with no effect on respiratory chain activity. In addition, the 
inhibitor protein was found to be associated with the dimeric form of the ATP 
synthase complex in control cells, being the distribution between monomeric 
and dimeric state of the enzyme unaffected by the absence of IF1 (the latter 
result implying that the inhibitor does not induce ATP synthase dimerization, 
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contrary to previous data reported (56) on IF1-F1 complexes). Therefore, the 
interaction of IF1 with the F1Fo-ATPase complex either directly, by increasing 
the catalytic activity of the enzyme, or indirectly, by improving the structure 
of mitochondrial cristae, can increase the oxidative phosphorylation rate in 
osteosarcoma cells grown under normoxic conditions.  
This aspect is of particular relevance, since the inhibitor has been long known 
to only inhibit ATP hydrolysis, whereas the observation that it can increase 
the ATP synthesis in mitochondria may represent a successful strategy used 
by cancer cells to produce more energy, giving a plausible explanation to the 
IF1 overexpression in cancer. Additionally, this facet is also relevant 
considering that the binding of IF1 is supposed to be strictly dependent on 
the environmental conditions to which tumor cells are exposed: as discussed 
above, it is well known that the inefficient development of vasculature within 
the tumor mass may expose tumor cells to a limited oxygen - and substrate – 
availability. As a consequence, both acidification of the matrix as well as a 
collapse in mitochondrial membrane potential may occur, inducing the 
binding of the inhibitor to the ATP synthase (141), but these conditions have 
only been marginally considered in recent studies.   
Therefore, further studies are currently ongoing to define the IF1 role in 
cancer, extending the investigation to include hypoxic and anoxic conditions, 
to better elucidate how the increase of the protein represents an efficacious 
strategy for cancer cells to survive and proliferate, facing - and successfully 
overcoming - all the circumstances these cells may encounter in the tumor 
microenvironment. 
 
In addition, a number of papers over the last decade indicated that cancer 
metabolism is greatly modulated by epigenetic alterations through 
endogenous RNA interference molecules, known as microRNAs (miRNAs). 
MiRNAs are small, noncoding RNA molecules of about 20-22 base in length, 
that bind to the 3'-untranslated region of target mRNA, affecting important 
cellular processes, like cell proliferation and differentiation, cell cycle, energy 
metabolism and other hallmarks of cancer, such as inhibition of apoptosis, 
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epithelial-to-mesenchymal transition (EMT), cell invasion and metastases 
and, more recently, they were addressed as responsible for chemoresistance 
in several common therapies (110).  
MicroRNAs deregulation in cancer was first demonstrated in 2002 (7), 
opening a new branch of investigation over cancer formation and 
progression: since then, accumulative studies showed that miRNAs play 
important roles in tumor growth by regulating oncogenes and tumor 
suppressor genes (142) (139). More intriguingly, a large number of miRNAs 
in the last few years have been identified to regulate cancer metabolism 
(140), pushing researchers to address the connection between cancer cells 
and specific miRNAs. Thus far, accumulating studies indicate that many of the 
well-known miRNAs relate to crucial genes that can impact metabolic 
pathways, both negatively and positively, by regulating the expression of 
genes/pathways/enzymes involved in glycolysis and energy metabolism. 
Therefore, studying the role of miRNAs is crucial in understanding their 
effect on metabolic pathways, and their ultimate effect on cancer cells, thus 
representing promising therapeutic targets, or therapeutic agents, in cancers.  
In an attempt to investigate over miRNAs contribution in regulating cancer 
cell metabolism in different cancer cell lines, during the permanence at the 
Children’s Hospital of Los Angeles, the miRNAs expression pattern was 
analyzed, to explore how these molecules alter metabolic and developmental 
pathways that can lead to cancer. However, while further investigations are 
currently ongoing to unravel miRNAs contribution in altering cancer 
metabolism, compelling data emerging from a microarray on different cell 
lines that included a sensitive- and a resistant-to-treatment melanoma cell 
lines, showed a specific pattern of miRNAs in the resistant cells, when 
compared to the sensitive ones. On the basis of the raised attention now 
given to the role exerted by microRNAs in triggering resistance to therapy, 
this peculiar miRNAs outline prompted us to further focus over this aspect, 
pushing us to deeper investigate on the molecular mechanisms induced by 
these molecules in a severe, challenging and yet poor-prognosis malignancy, 
like metastatic melanoma.  
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Indeed, microRNA expression profiling using microarrays (refer to (143) for 
details) revealed an up-regulation of four miRNAs in BRAF-I resistant 
melanoma cells M21-R when compared to the sensitive (M21) ones. 
Incidentally, three out of four miRNAs were predicted to target SUFU, the 
negative regulator of the GLI signaling cascade in the Sonic Hedgehog (Shh) 
pathway, crucially involved in the development of all vertebrates and 
recently reported to be deregulated in cancer. In addition, a recent paper 
specifically reported that the resistance to treatment in melanoma is 
mediated by Shh activation, which is induced by PDGFRα up-regulation 
(106). 
Being miR-136 the most expressed microRNA in this comparison, we 
primarily focus on the role exerted by this miR, validating these preliminary 
data, including other melanoma cell types in the study (i.e. Colo38 and 
Colo38-R and, partially, SK-Mel37 and Mel-37-R), and then analyzing the 
interconnection existing between the expression of miR-136 and the negative 
regulator of Shh pathway, SUFU, whose expression was evidently dependent 
on the content of the microRNA.  
Specifically, we showed that miR-136 has a protective role against BRAF-I 
treatment in sensitive melanoma cells, while inhibiting its expression in 
BRAF-I resistant cells partially restore the sensitivity to the drug in these 
cells (as summarized in Figure 53). Although the mechanism of microRNA-
mediated drug resistance is not fully understood, overall these emerging data 
encourage us to believe that melanoma cells trigger resistance to BRAF-I 
therapy by inducing the up-regulation of the three miRNAs, that down-
regulate SUFU and consequently activate Shh pathway. In addition, in vivo 
experiments have already been set up to further confirm these data in animal 
models, while future perspectives are also intended to investigate over the 
role exerted by the other up-regulated microRNAs, pointing towards the 
need for novel and more innovative therapeutic strategies to evade cancer 
drug resistance and fatal prognosis in metastatic melanoma patients. 
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Moreover, additional studies are currently ongoing to further explore how 
the treatment itself mediates the up-regulation of miR-136, contributing to 
the establishment of the BRAF-I resistance. Much more intriguingly, indeed, 
Figure 53: miR-136 can mediate BRAF-I resistance in BRAF(V600E) melanoma 
cells. Upon Sonic Hedgehog (Shh) ligand binding to its receptor Patched (Ptch), the 
repression of Smoothened (Smo) is relieved, resulting in the movement of Smo from the 
intracellular vesicles to the primary cilium. Activated Smo induces the Gli proteins, that 
enter the nucleus and promote transcription of the target genes, enhancing 
proliferation. This process is negatively regulated by the internal protein SUFU: in the 
absence of ligand, SUFU directly binds to GLI transcription factors and anchors them in 
the cytoplasm, thus facilitating their degradation (in addition, SUFU forms a repressor 
complex suppressing GLI1-induced gene expression inside the nucleus).  
BRAF(V600E) melanoma cells have a constitutive active BRAF→MEK1/2→ERK1/2 
MAP kinase pathway, leading to uncontrolled proliferation of cells, which can be 
counteracted by BRAF-I treatment, unless cells develop drug-resistance. Since miR-136 
targets SUFU (and its levels are higher in BRAF-I resistant melanoma cells, when 
compared to the sensitive ones), this molecule can likely modulate Shh pathway 
activity, affecting cell proliferation and drug sensitivity. Indeed, the induction of miR-
136 partially counteracts BRAF-I treament in melanoma sensitive cells, by decreasing 
SUFU and activating Shh pathway, while its down-regulation in BRAF-I resistant cells 
up-regulates SUFU, partially restoring sensitivity to BRAF-I treatment. 
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we showed that vemurafenib itself enhances miR-136 expression in 
melanoma sensitive-to-treatment cells, while concomitantly sustains higher 
levels in the under-treatment resistant melanoma cells.  
Being vemurafenib the major breakthrough in the treatment of  melanomas, 
it is conceivable to imagine that BRAF-I therapy (i.e. vemurafenib 
subministration), initially resulting in effective reduction of the tumor mass, 
later seemingly turns traitor by inducing the overexpression of the miRNAs 
mentioned above, eventually leading to BRAF-I resistance and tumor 
recurrence, in a much more aggressive form. Considering this hypothesis, an 
intermittent therapy, like the intermittent hormone therapy for prostate 
cancer (144), could be considered. Even more striking, once determined the 
effective roles exerted by all the four miRNAs in leading resistance to 
therapy, a combination of vemurafenib, together with small molecules 
inhibiting their overexpression could be a promising strategy to be 
considered, in the direction of donating new chances of survival and 
improved quality of life in poor prognosis melanoma patients.  
 
 
 
 
  
 Simona Barbato Pag. 113 
 
List of References 
 
1. Hallmarks of cancer: the next generation. Hanahan, D and Weinberg, RA. 5, 2011, 
Cell. , Vol. 144, pp. 646-74. 
2. The chemical constitution of respiration ferment. Warburg, O. 1928, Science, Vol. 68, 
pp. 437-443. 
3. Mitochondria and cancer. Wallace, DC. 2012, Nat. Rev. Cancer, Vol. 12, pp. 685–698. 
4. Tumors and Mitochondrial Respiration: A Neglected Connection. Viale, A, Corti, D and 
Draetta, GF. 2015, Cancer Res., Vol. 75, pp. 3685–3686. 
5. MicroRNAs and cancer epigenetics. Fabbri, M. 6, 2008, Curr Opin Investig Drugs., Vol. 
9, pp. 583-90. 
6. MicroRNAs. Fabbri M, Croce CM, Calin GA. 1, 2008, Cancer J. , Vol. 14, pp. 1-6. 
7. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 
13q14 in chronic lymphocytic leukemia. Calin, GA et al. 2002, Proc. Natl. Acad. Sci. U.S.A, 
Vol. 99, pp. 15524–15529. 
8. MicroRNAs and metabolism crosstalk in energy homeostasis. Dumortier, O, Hinault, C 
and Van Obberghen, E. 3, 2013, Cell Metab., Vol. 18, pp. 312-24. 
9. Exosomic microRNAs in the Tumor Microenvironment. Neviani, P and Fabbri, M. 47, 
2015, Front Med (Lausanne)., Vol. 2. 
10. The bioenergetic signature of cancer: a marker of tumor progression. Cuezva, J.M., 
Krajewska, M., de Heredia, M.L., Krajewski, S., Santamarıa, G.,Kim, H., Zapata, J.M., 
Marusawa, H., Chamorro, M., and Reed, J.C. 2002, Cancer Res., Vol. 64, pp. 6674–81. 
11. Evolutionary biology: essence of mitochondria. Henze K., and Martin W. 6963, 2003, 
Nature, Vol. 426, pp. 127-8. 
12. Altmann, Richard. Die Elementarorganismen. 1890. 
13. Common evolutionary origin of mitochondrial and rickettsial respiratory chains. 
Emelyanov, VV. 2003, Arch. Biochem. Biophys., pp. 130-41. 
14. Powerhouse of the cells. Siekevitz, Philip. 1957, Scientific American. 
15. Chemiosmotic coupling: the cost of living. Rich, P. 2003, Nature, p. 583. 
 Simona Barbato Pag. 114 
 
16. IF1: setting the pace of the F1F0-ATP synthase. Campanella, M. et al. 2009, Trends in 
Biochemical Sciences, pp. 343-350. 
17. Mitochondria and Ca2+ in cell physiology and pathophysiology. Duchen, M.R. 2000, 
Cell Calcium, Vol. 28, pp. 339-348. 
18. Mitochondrial control of apoptosis. Kroemer, G. et al. 1997, Immunol. Today, pp. 44-
51. 
19. Biochemical dysfunction in heart mitochondria exposed to ischaemia and 
reperfusion. Solaini, G and Harris, DA. 2005, Biochem J., pp. 377-94. 
20. Mitochondria are morphologically and functionally heterogeneous within cells. 
Collins TJ, Berridge MJ, Lipp P and Bootman MD. 7, 2002, The EMBO Journal, Vol. 21, 
pp. 1616-1627. 
21. An electron microscope study of themitochondrial structure. Palade, G.E. 1953, J. 
Histochem. Cytochem, pp. 188-211. 
22. Cardiolipin stabilizes respiratory chain supercomplexes. Pfeiffer K, Gohil V, Stuart 
RA, Hunte C, Brandt U, Greenberg ML, Schagger H. 278, 2003, J. Biol. Chem., pp. 52873-
80. 
23. Insight into mitochondrial structure and function from electron tomography. Frey 
T.G., Renken C.W., Perkins G.A. 2002, Biochim. Biophis. Acta, Vol. 1555, pp. 196-203. 
24. Structure and function of mitochondrial membrane protein complexes. Kuhlbrandt, 
W. 2015, BMC Biology, pp. 1-11. 
25. Ultrastructural bases for metabolically linked mechanical activity in mitochondria. I. 
Reversible ultrastructural changes with change in metabolic steady state in isolated liver 
mitochondria. Hackenbrock, CR. 2, 1966, J Cell Biol., Vol. 30, pp. 269-297. 
26. New Insights Into Structure and Function of Mitochondria and Their Role in Aging 
and Disease. Lenaz, G, Baracca, A, Fato, R, Genova, ML and Solaini, G. 3, 2006, 
ANTIOXIDANTS & REDOX SIGNALING, Vol. 8. 
27. Mitochondrial IF1 preserve cristae structure to limit apoptotic cell death signaling. 
Faccenda D., Tan H.T., Duchen M.R., Campanella M. 2013, Cell Cycle, pp. 2530-32. 
28. Hypoxia and mitochondrial oxidative metabolism. Solaini G, Baracca A, Lenaz G and 
Sgarbi G. 2010, Biochim Biophys Acta, pp. 1171-7. 
29. Mitochondrial fusion and fission in cell life and death. Westermann, B. 2010, 
Molecular Cell biology, pp. 872-884. 
30. Bioenergetic Origins of Complexity and Disease. Wallace, DC. 2011, Cold Spring Harb 
Symp Quant Biol, Vol. 76, pp. 1-16. 
 Simona Barbato Pag. 115 
 
31. the interplay between mitochondrial dynamics and mitophagy. Twig G., Shirihai OS. 
10, 2011, Antiox Redox Signal, Vol. 14, pp. 1939-51. 
32. Mitochondrial respiratory chain super-complex I–III in physiology and pathology. 
Lenaz G, Baracca A, Barbero G, Bergamini C, Dalmonte ME, Del Sole M, Faccioli M, 
Falasca A, Fato R, Genova ML, Sgarbi G and Solaini G. 2010, Biochimica et Biophysica 
Acta , Vol. 1797, pp. 633–640. 
33. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. 
Schagger H and Pfeiffer, K. 2000, The Embo journal, Vol. 19, pp. 1777-83. 
34. Assemblyof respiratory complexes I, III, and IV into NADH oxidase supercomplex 
stabilizescomplex I in Paracoccusdenitrificans. Stroh, A, Anderka O, Pfeiffer K, Yagi T, 
Finel M, Ludwig B, Schägger H. 2004, J. Biol. Chem., Vol. 279, pp. 5000–07. 
35. Supramolecular organization of cytochrome c oxidaseandalternative oxidase-
dependent respiratory chains in the filamentous fungus Podosporaanserina. Krause F, 
Scheckhuber CQ, Werner A, Rexroth S, Reifschneider NH, Dencher NA, Osiewacz HD. 
2004, J. Biol. Chem., Vol. 279, pp. 26453-61. 
36. Respiratory chain supercomplexes in plant mitochondria. Eubel, H., Heinemeyer, J., 
Sunderhaus, S, Brau, HP. 2004, Plant Physiol. Biochem., Vol. 42, pp. 937-42. 
37. Defining the mitochondrial proteosomes from five rat organs in a physiologically 
significant context usind 2D Blue-Native/SDS-PAGE. Reifschneider NH, Goto S, 
Nakamoto H, Takahashi R, Sugawa M, Dencher NA, Krause F. 2006, J. Proteome Res., 
pp. 1117-32. 
38. Significance of respirasomes for the assembly/stability of human respiratory chain 
complex I. Schagger H., De Coo R., Bauer MF., Hoffmann S., Godinot C., Brandt U. 
279(35), 2004, J Biol Chem., pp. 36349-53. 
39. Is supercomplex organization of the respiratory chain required for optimal electron 
transfer activity. Genova ML, Baracca A, Biondi A, Casalena G, Faccioli M, Falasca AI, 
Formiggini G, Sgarbi G, Solaini G and Lenaz G. 2008, Biochim. Biophys. Acta, Vol. 1777, 
pp. 740–746. 
40. Mitochondrial Complex I: structure, function, and implications in neurodegeneration. 
Lenaz G, Baracca A, Fato R, Genova ML, Solaini G. 3-4, 2006, Ital J Biochem. , Vol. 55, 
pp. 232-53. 
41. The quaternary structure of the Saccharomyces cerevisiae succinate dehydrogenase. 
Homology modeling, cofactor docking, and molecular dynamics simulation studies. 
Oyedotun, KS and Lemire, BD. 279, 2004, J. Biol. Chem., Vol. 5, pp. 9424-31. 
 Simona Barbato Pag. 116 
 
42. Q-cycle bypass reactions at the Q site of cyochrome bc1 (and related) complexes. 
Kramer DM, Roberts AG, Muller F, Cape J, Bowman MK (2004) Q-cycle. 2004, Methods 
Enzymol, Vol. 382, pp. 21-45. 
43. Inhibitors of the catalytic domain of mitochondrial ATP synthase. Gledhill JR and 
Walker, JE. 2006, Biochem Soc Trans. , Vol. 34, pp. 989-92. 
44. The peripheral stalk of the mitochondrial ATP synthase. Walker, JE and Dickinson, 
VK. 2006, Biochim. Biophys. Acta, Vol. 1757, pp. 286-96. 
45. The ATP synthase: the understood, the uncertain and the unknown. Walker, JE. 2013, 
Keilin Memorial Lecture, pp. 1-16. 
46. A model for conformational coupling of membrane potential and proton 
translocation to ATP synthesis and to active transport. Boyer, PD. 58, 1975, FEBS letter, 
Vol. 15, pp. 1-6. 
47. The binding change mechanism for ATP synthase: some probabilities and 
possibilities. Boyer, P D. 1993, Biochim.Biophys. Acta, pp. 215-30. 
48. The regulation of catalysis in ATP synthase. Walker, JE. 1994, Current Opinion in 
Structural Biology, pp. 912-18. 
49. Post-transcriptional regulation of the mitochondrial H+-ATP synthase: a key regulator 
ofthe metabolic phenotype in cancer. Willers, IM and Cuezva, JM. 06, 2011, Biochimica 
et Biophysica Acta, Vol. 1807, pp. 543-51. 
50. Structure of the yeast F1Fo-ATP synthase dimer and its role in shaping the 
mitochondrial cristae. Karen M. Davies, Claudio Anselmi, Ilka Wittig, José D. Faraldo-
Gómez and Werner Kühlbrandt. 34, 2012, PNAS, Vol. 109, pp. 13602–07. 
51. Dimer ribbons of ATPsynthase in native mitochondrial inner membranes. Strauss M, 
Hofhaus G, Schroder RR and W Kuhlbrandt. 2007, EMBO J., pp. 2870-76. 
52. An investigation of mitochondrial inner membranes by rapid-freeze deep-etc 
techniques. Allen RD, Schroeder CC and Frok AK. 1989, J. Cell Biol., pp. 2233-40. 
53. A naturally occurring inhibitor of mitochondrial adenosine triphosphatase. Pullman, 
ME and Monroy, GC. 1963, The Journal of Biological Chemistry, Vol. 238, pp. 3762-69. 
54. Protonic inhibition of the mitochondrial adenosine 50-triphosphatase in ischemic 
cardiac muscle. eversible binding of the ATPase inhibitor protein to the mitochondrial 
ATPase during ischemia. Rouslin, W. and Pullman, M.E. 1987, J. Mol. Cell. Cardiol., Vol. 
19, pp. 661-68. 
55. ATPase activity, IF1 content, and proton conductivity of ESMP from control and 
ischemic slow and fast heartrate hearts. . Rouslin, W. et al. 1995, J. Bioenerg. 
Biomembr, Vol. 27, pp. 459-66. 
 Simona Barbato Pag. 117 
 
56. Dimerization of Bovine F1-ATPase by Binding the Inhibitor Protein, IF1. Cabezón, E., 
Arechaga, I., Jonathan, P., Butler, G. and John E. Walker. 2000, J. Biol. Chem., pp. 
28353-55. 
57. Faccenda, D and Campanella, M. 2012, International Journal of Cell Biology. 
58. Binding of the Inhibitor Protein IF1 to Bovine F1-ATPase. Bason, JE, Runswick, MJ, 
Fearnley, IM and John E. Walker. 2011, J. Mol. Biol., Vol. 404, pp. 443-53. 
59. Regulation of mitochondria structure and function by the F1F0-ATPase inhibitor 
protein,IF1. Campanella M, Casswell E,Chong S et al. 2008, Cell Metabolism, Vol. 8, pp. 
13-25. 
60. The inhibitor protein (IF1) promotes dimerization of the mitochondrial F1F0-ATP 
synthase. Garcia, JJ, Morales-Ríos E, Cortés-Hernández P, and Rodríguez-Zavala, JS. 42, 
2006, Biochemistry, Vol. 45, pp. 12695-703. 
61. IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. 
Faccenda, D, Tan, CH, Seraphim, A, Duchen, MR and Campanella, M. 2013, Cell Death 
and Differentiation , pp. 1-12. 
62. Dimerization of F0F1ATP synthase from bovine heart is independent from the binding 
of the inhibitor protein IF1. Tomaseting, L, Di Pancrazio, F, Harris, DA, Mavelli, I and 
Lippe, G. 2002, Biochimica et Biophysica Acta, Vol. 1556, pp. 133-141. 
63. IF1, the endogenous regulator of the F1Fo-ATPsynthase, defines mitochondrial 
volume fraction in HeLa cells by regulating autophagy. Campanella, M Seraphim, A, 
Abeti R, Casswell E, Echave P, and Duchen, MR. 2009, Biochimica et Biophysica Acta, 
Vol. 1787, pp. 393-41. 
64. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde 
prosurvival and proliferative response. Formentini, L, Sanchez-Arago, M, Sanchez-
Cenizo, L and J. M. Cuezva. 6, 2012, Molecular Cell., Vol. 45, pp. 731–742. 
65. Up-regulation of the ATPase Inhibitory factor 1 (IF1) of the mitochondrial ATP 
synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg 
phenotype. Sanchez-Cenizo, L., Formentini, L., Aldea, M., Ortega, AD, Garcia-Huerta, P., 
Snchez-Aragò, M. and J. Cuezva. 33, 2010, J. Biol. Chem., Vol. 285. 
66. Increased content of natural ATPase inhibitor in tumor mitochondria. Luciakova, K. 
and Kuzela, S. 1, 1984, The FEBS Letters, Vol. 177, pp. 85–88. 
67. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Ortega, S, Malumbres, M 
and Barbacid, M. 2002, Biochim. Biophys. Acta , Vol. 1602, pp. 73–87. 
68. The retinoblastoma tumour suppressor in development and cancer. Classon, M and 
Harlow, E. 2002, Nat. Rev. Cancer, pp. 910–917. 
 Simona Barbato Pag. 118 
 
69. DNA damage and repair. Friedberg, EC. 2003, Nature, Vol. 421, pp. 436-440. 
70. Mutations affecting segment number and polarity in Drosophila. Nusslein-Volhard, C 
and Weischaus, E. 1980, Nature, Vol. 287, pp. 795-801. 
71. Hedgehog: functions and mechanisms. Varjosalo, M and Taipale, J. 2008, Genes 
Dev., pp. 2454-72. 
72. Hedgehog signaling. Varjosalo M. and Taipale, J. 2007, J.Cell. Sci., Vol. 120, pp. 3-6. 
73. A genome-wide RNA interference screen in Drosophila melanogaster cells for new 
components of the Hh signaling pathway. Nybakken, K, Vokes, SA, Lin, TY, McMahon, 
AP and Perrimon, N. 2005, Nat. Genet., Vol. 37, pp. 1323-32. 
74. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated 
in the regulation of CNS polarity. Echelard, Y., et al., et al. 1993, Cell., Vol. 75, pp. 1417–
1430. 
75. A functionally conserved homolog of the drosophila segment polarity gene hh is 
expressed in tissues with polarizing activity in zebrafish embryos. Krauss, S, Concordet, 
J.P. and Ingham, P.W. 1993, Cell, Vol. 75, pp. 1431–1444. 
76. Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of of 
hedhegoh expressed by the notochord. Roelink, H., et al., et al. 1994, Cell, Vol. 76, pp. 
761-775. 
77. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify 
prospective neuroctodermal cell fate in the mouse embryo. Dyer, MA, Farrington, SM, 
Mohn, D, Munday, JR and Baron, MH. 2001, Development, Vol. 30, pp. 1717-30. 
78. Regulation of cartilage dufferentiation by Indian hedgehog and PTH-related protein. 
Vortkamp, A, Lee, K, Lankse, B, Segre, GV, Kronenberg, HM and Tabin, CJ. 1996, 
Science, Vol. 273, pp. 613-622. 
79. Functional differences among Xenophis nodal-related genes in left-right axis 
determination. Sampath, K, Cheng, AM, Frisch, A and Wright, CV. 1997, Development, 
Vol. 124, pp. 3293-3302. 
80. Communicating with Hedgehogs. Hooper, JE and Scott, MP. 2005, Nat. Rev. Mol. 
Cell. Biol., Vol. 6, pp. 306-17. 
81. Patched acts catalytically to suppress the activity of Smoothened. Taipale, J, Cooper, 
MK, Maiti, T and Beachy, PA. 2002, Nataure, Vol. 418, pp. 892-97. 
82. Catching a Gli-mpse of Hedgehog. Ruiz-Altaba, A. 1997, Cell., Vol. 90, pp. 193-96. 
83. Gli proteins in development and disease. Hui, C.C.and Angers, S. 2011, Annu. Rev. 
Cell Dev. Biol., Vol. 27, pp. 513–537. 
 Simona Barbato Pag. 119 
 
84. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. 
Scales, S.J. and de Sauvage, F.J. 2009, Trends Pharmacol. Sci., Vol. 30, pp. 303–312. 
85. Context-dependent regulation of the Gli code in cancer by hedgehog and non-
hedgehog signals. Stecca, B. and Ruiz, I.A.A. 2010, J. Mol. Cell Biol., Vol. 2, pp. 84–95. 
86. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. 
Kogerman, P., et al., et al. 1999, Nat. Cell. Biol. , pp. 312–319. . 
87. Identification of Shhas a caandidate gene responsible for holoprosencephaly. Belloni, 
E, Muenke, M, Roessler, E, Traverso, G, Siegel-Bartelt, J, Frumkin, A et al. 1996, Nat. 
Gen., pp. 353-56. 
88. mutations in thr human Sh genecause holoprosencephaly. Roessler E, Belloni E, 
Gaudenz K, Berta P, Scherer SW et al. 1996, Nat. Gen., pp. 357-60. 
89. The hedgehog response network: Sensors, switches, and routers. Lum, L. and Beachy, 
P.A. 2004, Science, Vol. 304, pp. 1755-59. 
90. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. Gorlin, R.J. and Goltz, 
R.W. 1960, N. Engl. J. Med., Vol. 212, pp. 908-12. 
91. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. 
Kimonis, V.E., et al., et al. 1997, Am. J. Med. Genet., Vol. 69, pp. 299-308. 
92. Hedhehog signalling within airway epithelial progenitors and in small-cell lung 
cancer. Watkins, DN, Berman, DM, Burkholder, SG, Wang, B, Beachy, PA and Baylin, 
SB. 2003, Nature, Vol. 422, pp. 313–317. 
93. Human colon cancer epithelial cells harbour active hedgehog-GLI signalling that is 
essential for tumour growth, recurrence, metastasis and stem cell survival and 
expansion. Varnat, F., et al., et al. 2009, EMBO Mol. Med., Vol. 1, pp. 338–351. 
94. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Karhadkar, 
S.S., et al., et al. 2004, Nature, pp. 707–712. 
95. The gain-of-function GLI1 transcription factor tGLI1 enhances expression of VEGF-C 
and TEM7 to promote glioblastoma angiogenesis. Carpenter, RL, Paw, I, Zhu, H, 
Sirkisoon, S and Xing, F. 2015, Oncotarget, Vol. 6, pp. 22653–22665. 
96. Tumor-host interactions: a far-reaching relationship. Mcallister, SS and Weinberg, 
RA. 2010, J Clin Oncol, Vol. 28, pp. 4022–8. 
97. A paracrine requirement for hedgehog signalling in cancer. Yauch, R.L., et al., et al. 
2008, Nature, Vol. 455, pp. 406–410. 
98. Melanoma and the tumor microenvironment. Villanueva, J and Herlyn, M. 2008, 
Curr Oncol Rep, Vol. 10, pp. 439-46. 
 Simona Barbato Pag. 120 
 
99. Focus on melanoma. Houghton AN, and Polsky D. 4, 2002, Cancer Cell., Vol. 2, pp. 
275–278. 
100. Global cancer statistics, 2002. Parkin D, Bray F, Ferlay J, and Pisani P. 2, 2005, CA 
Cancer J Clin, Vol. 55, pp. 74-108. 
101. Early detection and treatment of skin cancer. Jerant AF, Johnson JT, Sheridan CD 
and Caffrey TJ. 2, 2000, Am Fam Physician, Vol. 62, pp. 357–68, 375–6, 381–2. 
102. BRAF as therapeutic target in melanoma. . Wellbrock, C and Hurlstone, A. 2010, 
Biochem Pharmacol., pp. 561-567. 
103. Mutations of the BRAF gene in human cancer. Davies H, Bignell GR, Cox C, et al. 
2002, Nature., Vol. 417, pp. 949-954. 
104. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Smalley, 
KS. 5, 2003, Int J Cancer., Vol. 104, pp. 527–532. 
105. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between 
GLI1 and the RAS-MEK/AKT pathways. Stecca B, Mas C, Clement V, Zbinden M, Correa 
R, Piguet V, Beermann F and Ruiz IAA. 14, 2007, PNAS, Vol. 104, pp. 5895-5900. 
106. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to 
BRAF inhibitor resistance in melanoma cells with BRAF mutation. Sabbatino F, Wang Y, 
Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, 
Frederick DT, Wargo JA, Ferrone S, and Ferrone CR. 7, 2013, Oncotarget, Vol. 5, pp. 
1926-41. 
107. GLI2-mediated melanoma invasion and metastasis. Vasileia-Ismini Alexaki, 
Delphine Javelaud, Leon C. L. Van Kempen, Khalid S. Mohammad, Sylviane Dennler, 
Flavie Luciani, Keith S. Hoek, Patricia Juàrez, James S. Goydos, Pierrick J. Fournier, 
Claire Sibon, Corine Bertolotto, Franck Verrecchia, et al. 2010, JNCI, pp. 1148-59. 
108. Malignant melanoma: genetics and therapeutics in the genomic era. Chin L, 
Garraway LA, and Fisher, DE. 16, 2006, Genes Dev., Vol. 20, pp. 2149–2182. 
109. Treatment of metastatic melanoma: an overview. Bhatia S, Tykodi SS and 
Thompson JA. 2009, Oncology. , Vol. 23, pp. 488-496. 
110. MicroRNAs and cancer resistance: A new molecular plot. Fanini, F and Fabbri, M. 
Clin. Pharacol. Ther. : s.n., 2016. 
111. MicroRNAs as new therapeutic targets and tools in cancer. Gandellini P, Profumo 
V, Folini M and Zaffaroni N. 2011, Expert Opin Ther Targets , Vol. 15, p. 265 279. 
112. Hypoxia inducible factor-1α as a therapeutic target in multiple myeloma. Borsi, E., 
Perrone, G., Terragna, C., Martello, M., Dico, A. F., Solaini, G., Baracca, A., Sgarbi, G., 
 Simona Barbato Pag. 121 
 
Pasquinelli, G., Valente, S., Zamagni, E., Tacchetti, P., Martinelli, G., and Cavo, M. 2014, 
Oncotarget, Vol. 5, pp. 1779–1792. 
113. Protein measurement with the Folin phenol reagent. Lowry OH, Rosebrough NJ, 
Farr AL, Randall RJ. 1951, J Biol Chem, Vol. 193, pp. 265-275. 
114. Stabilization of mitochondrial functions with digitonin. Kun, E., Kirsten, E., and 
Piper, W. N. 1979, Methods Enzymol., Vol. 55, pp. 115-18. 
115. The Inhibitor Protein (IF1) of the F1F0-ATPase Modulates Human Osteosarcoma Cell 
Bioenergetics. Barbato S, Sgarbi G., Gorini G., Baracca A., Solaini G. 10, 2015, J Bio 
Chem., Vol. 290, pp. 6338-48. 
116. Oxidative phosphorylation in cancer cells. Solaini, G., Sgarbi, G., and Baracca, A. 
2011, Biochim. Biophys. Acta, Vol. 1807, pp. 534–542. 
117. Quantification of muscle mitochondrial oxidative phosphorylation enzymes via 
histochemical staining of blue native polyacrylamide gels. Zerbetto, E., Vergani, L., and 
Dabbeni-Sala, F. 1997, Electrophoresis, Vol. 18, pp. 2059–2064. 
118. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-
ras transformed cells. Baracca, A., Chiaradonna, F., Sgarbi, G., Solaini, G., Alberghina, 
L., and Lenaz, G. 2010, Biochim. Biophys. Acta, Vol. 1797, pp. 314–323. 
119. Mitochondria hyperfusion and elevated autophagic activity are key mechanisms for 
cellular bioenergetic preservation in centenarians. Sgarbi G, Matarrese P, Pinti M, 
Lanzarini C, Ascione B, Gibellini L, Dika E, Patrizi A, Tommasino C, Capri M, Cossarizza 
A, Baracca A, Lenaz G, Solaini G, Franceschi C, Malorni W, Salvioli S. 2014, Aging, Vol. 6, 
pp. 296-310. 
120. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, 
lymphoblasts, and transmitochondrial cell lines. Trounce IA, Kim YL, Jun AS, Wallace DC. 
1996, Methods Enzymol , Vol. 264, pp. 484-509. 
121. Hyperoxia fully protects mitochondria of explanted livers. Sgarbi G, Giannone F, 
Casalena GA, Baracca A, Baldassarre M, Longobardi P, Caraceni P, Derenzini M, Lenaz 
G and Solaini G. 6, 2011, J Bioenerg Biomembr. , Vol. 43, pp. 673-82. 
122. Biochemical phenotypes associated with the mitochondrial ATP6gene mutations at 
nt8993. Baracca A, Sgarbi G, Mattiazzi M, Casalena G, Pagnotta E, Valentino ML, 
Moggio M, Lenza G, Carelli V and Solaini G.  
123. Glucose plays a main role in human fibroblasts adaptation to hypoxia. Baracca, A., 
Sgarbi, G., Padula, A., and Solaini, G. 2013, J. Biochem. Cell Biol., Vol. 45, pp. 1356–
1365. 
 Simona Barbato Pag. 122 
 
124. Inefficient coupling between proton transport and ATP synthesis may be the 
pathogenic mechanism for NARP and Leigh syndrome resulting from the T8993G 
mutation in mtDNA. Sgarbi G, Baracca A, Lenaz G, Valentino LM, Carelli V, Solaini G. 
2006, Biochem J, Vol. 395, pp. 493-500. 
125. Tryptophan phosphorescence as a structural probe of mitochondrial F1-ATPase-
subunit. Solaini G, Baracca A, Parenti Castelli G, and Strambini GB. 1993, Eur. J. 
Biochem., Vol. 214, pp. 729–734. 
126. Determination of blood glucose using 4-amino phenazone as oxyen acceptor. 
Trinder, P. 2, 1969, J Clin Pathol., Vol. 22, p. 246. 
127. MicroRNA targets in Drosophila. Enright, A.J., John,B., Gaul,U., Tuschl,T., Sander,C. 
and Marks, D.S. 2003, Genome Biol.,, p. R1. 
128. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Dweep, H et 
al. 8, 2015, Nature Methods, Vol. 12, p. 697. 
129. Sutherland, RM. 1988, Science, Vol. 240, pp. 177-84. 
130. Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in 
human cancers. Sánchez-Aragó M1, Formentini L, Martínez-Reyes I, García-Bermudez J, 
Santacatterina F, Sánchez-Cenizo L, Willers IM, Aldea M, Nájera L, Juarránz A, López 
EC, Clofent J, Navarro C, Espinosa E, Cuezva JM. 2, 2013, Oncogenesis, Vol. 22. 
131. Assessing actual contribution of IF1, inhibitor of mitochondrial F0F1, to ATP 
homeostasis, cell growth, mitochondrial morphology, and cell viability. . Fujikawa, M., 
Imamura, H., Nakamura, J., and Yoshida, M. 2012, J. Biol. Chem., Vol. 287, pp. 18781–
18787. 
132. Up-regulation of the ATPase Inhibitory Factor 1 (IF1) of the Mitochondrial H+-ATP 
Synthase in Human Tumors Mediates the Metabolic Shift of Cancer Cells to a Warburg 
Phenotype. Sànchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, 
Sanchez-Aragò M, and José M. Cuezva. 33, 2010, JBC, Vol. 285, pp. 25308-13. 
133. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. 
Sánchez-Aragó M, Formentini L, García-Bermúdez J and José M. Cuezva. 16, 2012, Cell 
Cycle, Vol. 11. 
134. Lack of major changes in ATPase activity in mitochondria from liver, heart, and 
skeletal muscle of rats upon ageing. Barogi, S., Baracca, A., Parenti Castelli, G., Bovina, 
C., Formiggini, G., Marchetti, M., Solaini, G., and Lenaz, G. 1995, Mech. Ageing D, Vol. 
84, pp. 139-50. 
135. Modification of the mitochondrial F1-ATPase epsilon subunit, enhancement of the 
ATPase activity of the IF1-F1 complex and IF1-binding dependence of the conformation 
 Simona Barbato Pag. 123 
 
of the epsilon subunit. Solaini G, Baracca A, Gabellieri E, Lenaz G. 327, 1997, Biochem J. 
, Vol. 15, pp. 443-8. 
136. IF1: setting the pace of the F1Fo-ATP synthase. Campanella M, Parker N, Tan CH, 
Hall AM and Duchen MR. 2009, Cell Press, pp. 343-50. 
137. Purification and characterization of adenosine triphosphatase from eel liver 
mitochondria. Baracca, A., Degli Esposti, M., Parenti Castelli, G., and Solaini, G. 1992, 
Comp. Biochem. Physiol. , pp. 421-26. 
138. Modulation of the oligomerization state of the bovine F1-ATPase inhibitor protein, 
IF1, by pH. Cabezon, E., Butler, P. J., Runswick, M. J., and Walker, J. E. 2000, J. Biol. 
Chem., Vol. 275, pp. 25460–64. 
139. MicroRNA signatures in human cancers. Calin, GA and Croce, CM. 11, 2006, Nat. 
Rev. Cance, Vol. 6, pp. 857–866. 
140. Regulation of cancer cell metabolism. Cairns, RA, Harris, IS and Mak, TW. 2, 2011, 
Nat. Rev. Cancer , Vol. 11, pp. 85-95. 
141. Control of mitochondrial ATP synthesis. Harris, DA and Das, AM. 1991, Biochem. J. , 
Vol. 280, pp. 561–573. 
142. The microcosmos of cancer. Lujambio A. and Lowe, SW. 7385, 2012, Nature, Vol. 
482, pp. 347–355. 
143. MicroRNA expression profiling using microarrays. Liu CG, Calin GA, Volinia S and 
Croce CM. 4, 2008, Nat Protoc. , Vol. 3, pp. 563-78. 
144. Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen 
resistant metastases. Chauvin, HF. 12 Pt 2, 1973, Vol. 79, pp. 397-8. 
145. MiR 133a is functionally involved in doxorubicin resistance in breast cancer cells 
MCF 7 via its regulation of the expression of uncoupling protein 2. Yuan Y, Yao YF, Hu 
SN, Gao J and Zhang LL. 2015, PLoS One . 
 
 
